



Modular Program Report

The following report(s) provides findings from an FDA-initiated query using its Mini-Sentinel pilot. While Mini-Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Mini-Sentinel, and seeking to better understand the capabilities of the Mini-Sentinel pilot.

Data obtained through Mini-Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from the Mini-Sentinel pilot in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Mini-Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Mini-Sentinel Operations Center for assistance at info@mini-sentinel.org.

Overview

Request Description

FDA requested execution of Modular Program #5 (MP5), version 2.1, to investigate prevalent and incident use of pneumococcal conjugate vaccines (PCV7, PCV13, and Generic PCV) as well as prevalent and incident diagnoses of Kawasaki's Disease (ICD-9 446.1). In addition, FDA requested use of Modular Program #3 (MP3), version 2.5, to investigate diagnosis of Kawasaki's Disease following incident vaccination with pneumococcal conjugate vaccines (PCV7, PCV13, and Generic PCV). The queries were run against the Mini-Sentinel Distributed Database (MSDD) for the time period of January 1, 2000 - March 31, 2012. However, data were only available for the time period of January 1, 2004 - March 31, 2012. This request was distributed to 3 Data Partners on August 8, 2012, and to a fourth Data Partner on September 21, 2012. This report includes data from 4 Data Partners.

Results of MP5 provide prevalent and incident counts of members receiving pneumococcal vaccine, and counts of vaccination codes, eligible members (denominator), member-days, members vaccinated per 1,000 eligible members, and vaccinations per members vaccinated. MP5 also provides prevalent and incident counts of patients diagnosed with Kawasaki's Disease, Kawasaki's Disease events, eligible members (denominator), member days, patients per 1,000 eligible members, and Kawasaki's Disease events per patient.

Results of MP3 provide incident counts and percent of members receiving pneumococcal vaccine, treatment episodes, eligible members (denominator), and member days. Counts of Kawasaki's Disease events, days at risk, members vaccinated per 1,000 eligible members, and events per 10 Million days at risk following exposure to pneumococcal vaccine are also presented.

Request ID

msy3_mpr39

Specifications

Program parameter inputs and scenarios.

Glossary

List of terms found in this report and their definitions.

Table 1a

Table displaying the number of prevalent and incident members vaccinated, number of new vaccines, total number of vaccines, eligible members, member-days, members vaccinated per 1,000 eligible members, and vaccinations per member vaccinated by vaccine in members aged 0-72 months - January 1, 2004 - March 31, 2012.

Table 1b

Table displaying the number of prevalent and incident patients, number of new events, total number of events, eligible members, member-days, patients per 1,000 eligible members, and events per patient by principal diagnosis indicator in members aged 0-72 months - January 1, 2004 - March 31, 2012.

Table 1c

Table displaying incident members newly vaccinated, new treatment episodes, eligible members, member-days, days at risk, number of events, new members vaccinated per 1,000 eligible members, and number of events per 10,000,000 days at risk by vaccine, episode extension period, and principal diagnosis indicator in members aged 0-72 months - January 1, 2004 - March 31, 2012.

Table 2a

Table displaying the number of prevalent and incident members vaccinated, number of new vaccines, total number of vaccines, eligible members, member-days, members vaccinated per 1,000 eligible members, and vaccinations per member vaccinated by vaccine and age group in members aged 0-72 months - January 1, 2004 - March 31, 2012.

Table 2b

Table displaying the number of prevalent and incident patients, number of new events, total number of events, eligible members, member-days, patients per 1,000 eligible members, and events per patient by principal diagnosis indicator and age group in members aged 0-72 months - January 1, 2004 - March 31, 2012.

Overview (Continued)

<u>Table 2c</u>	Table displaying incident members newly vaccinated, new treatment episodes, eligible members, member-days, days at risk, number of events, new members vaccinated per 1,000 eligible members, and number of events per 10,000,000 days at risk by vaccine, episode extension period, principal diagnosis indicator, and age in members aged 0-72 months - January 1, 2004 - March 31, 2012.
<u>Table 3a</u>	Table displaying the number of prevalent and incident members vaccinated, number of new vaccines, total number of vaccines, eligible members, member-days, members vaccinated per 1,000 eligible members, and vaccinations per member vaccinated by vaccine and sex in members aged 0-72 months - January 1, 2004 - March 31, 2012.
<u>Table 3b</u>	Table displaying the number of prevalent and incident patients, number of new events, total number of events, eligible members, member-days, patients per 1,000 eligible members, and events per patient by principal diagnosis indicator and sex in members aged 0-72 months - January 1, 2004 - March 31, 2012.
<u>Table 3c</u>	Table displaying incident members newly vaccinated, new treatment episodes, eligible members, member-days, days at risk, number of events, new members vaccinated per 1,000 eligible members, and number of events per 10,000,000 days at risk by vaccine, episode extension period, principal diagnosis indicator, and sex in members aged 0-72 months - January 1, 2004 - March 31, 2012.
<u>Table 4a</u>	Table displaying the number of prevalent and incident members vaccinated, number of new vaccines, total number of vaccines, eligible members, member-days, members vaccinated per 1,000 eligible members, and vaccinations per member vaccinated by vaccine and year in members aged 0-72 months - January 1, 2004 - March 31, 2012.
<u>Table 4b</u>	Table displaying the number of prevalent and incident patients, number of new events, total number of events, eligible members, member-days, patients per 1,000 eligible members, and events per patient by principal diagnosis indicator and year in members aged 0-72 months - January 1, 2004 - March 31, 2012.
<u>Table 4c</u>	Table displaying incident members newly vaccinated, new treatment episodes, eligible members, member-days, days at risk, number of events, new members vaccinated per 1,000 eligible members, and number of events per 10,000,000 days at risk by vaccine, episode extension period, principal diagnosis indicator, and year in members aged 0-72 months - January 1, 2004 - March 31, 2012.
<u>Appendix A</u>	List of exposure procedure and diagnosis codes used in this request.
Notes:	Please contact the Mini-Sentinel Operations Center (MSOC_Requests@harvardpilgrim.org) for questions and to provide comments/suggestions for future enhancements to this document.

Modular Program Specifications for MSY3_MPR39 - MP5

Modular Program #5, version 2.1, was used to investigate prevalent and incident use of pneumococcal conjugate vaccines and diagnoses of Kawasaki's Disease (see Appendix A for code list). In total, 5 different scenarios were examined in this request. See below for a description of each of these scenarios.

Query Period	January 1, 2000 to March 31, 2012
Enrollment Gap	45 Days
Age Stratifications	0M-1M 1M-2M 2M-3M 3M-4M 4M-5M 5M-6M 6M-7M 7M-8M 8M-9M 9M-10M 10M-11M 11M-12M 12M-13M 13M-14M 14M-15M 15M-16M 16M-17M 17M-18M 18M-19M 19M-20M 20M-21M 21M-22M 22M-23M 23M-24M 24M-25M 25M-26M 26M-27M 27M-28M 28M-29M 29M-30M 30M-31M 31M-32M 32M-33M 33M-34M 34M-35M 35M-36M 36M-37M 37M-38M 38M-39M 39M-40M 40M-41M 41M-42M 42M-43M 43M-44M 44M-45M 45M-46M 46M-47M 47M-48M 48M-49M 49M-50M 50M-51M 51M-52M 52M-53M 53M-54M 54M-55M 55M-56M 56M-57M 57M-58M 58M-59M 59M-60M 60M-61M 61M-62M 62M-63M 63M-64M 64M-65M 65M-66M 66M-67M 67M-68M 68M-69M 69M-70M 70M-71M 71M-72M

Scenario	Drug/Exposure					
	Incident exposure	Incident w/respect	Washout (days)	Incidence Type*	Care Setting**	Principal Dx**
1	PCV7	PCV7	14	Multiple	NA	NA
2	PCV13	PCV13	14	Multiple	NA	NA
3	Generic PCV	Generic PCV, PCV7, PCV13	14	Multiple	NA	NA
4	Kawasaki's Disease	Kawasaki's Disease	14	Minimum	Any	NO
5	Kawasaki's Disease	Kawasaki's Disease	14	Minimum	IP	YES

***Multiple incidence type for the vaccinations** will consider incident vaccinations for each user during the query period that satisfies the Washout Period criteria (14 days). Under this condition, a user may have more than one incident vaccination. The **Minimum incidence type for the diagnosis** will only consider a diagnosis under the condition that the user has no prior history of the diagnosis (no time restriction). There may only be one diagnosis per user.

**Caresetting and Principal Dx parameters apply to Kawasaki's Disease diagnoses only

Modular Program Specifications for MSY3_MPR39 - MP3

Modular Program #3, version 2.5, was used to investigate diagnosis of Kawasaki's Disease following incident vaccination with pneumococcal conjugate vaccine (see Appendix A for code list). In total, 12 different scenarios were examined in this request. See below for a description of each of these scenarios.

Query Period January 1, 2000 to March 31, 2012
Enrollment Gap 45 Days
Age Stratifications 00M-03M 04M-05M 06M-11M 12M-23M 24M-59M 60M-71M

Scenario	Drug/Exposure							Event/Outcome						
	Incident exposure	Incident w/ respect to:	Washout (days)	Incidence Type*	Episode gap	Extension period	Min episode duration	Min days supplied	Event/ Outcome	Washout (days)	Incidence Type**	Care Setting	Principal Dx	Blackout Period
1	PCV7	PCV7	14	Multiple	0	14	0	0	Kawasaki's Disease	14	Minimum	ED, IP, AV	NO	1
2	PCV7	PCV7	14	Multiple	0	14	0	0	Kawasaki's Disease	14	Minimum	IP	YES	1
3	PCV7	PCV7	14	Multiple	0	28	0	0	Kawasaki's Disease	14	Minimum	ED, IP, AV	NO	1
4	PCV7	PCV7	14	Multiple	0	28	0	0	Kawasaki's Disease	14	Minimum	IP	YES	1
5	PCV13	PCV13	14	Multiple	0	14	0	0	Kawasaki's Disease	14	Minimum	ED, IP, AV	NO	1
6	PCV13	PCV13	14	Multiple	0	14	0	0	Kawasaki's Disease	14	Minimum	IP	YES	1
7	PCV13	PCV13	14	Multiple	0	28	0	0	Kawasaki's Disease	14	Minimum	ED, IP, AV	NO	1
8	PCV13	PCV13	14	Multiple	0	28	0	0	Kawasaki's Disease	14	Minimum	IP	YES	1
9	Generic PCV	Generic PCV, PCV7, PCV13	14	Multiple	0	14	0	0	Kawasaki's Disease	14	Minimum	ED, IP, AV	NO	1
10	Generic PCV	Generic PCV, PCV7, PCV13	14	Multiple	0	14	0	0	Kawasaki's Disease	14	Minimum	IP	YES	1
11	Generic PCV	Generic PCV, PCV7, PCV13	14	Multiple	0	28	0	0	Kawasaki's Disease	14	Minimum	ED, IP, AV	NO	1
12	Generic PCV	Generic PCV, PCV7, PCV13	14	Multiple	0	28	0	0	Kawasaki's Disease	14	Minimum	IP	YES	1

*Multiple incidence type for the exposure will consider incident episodes for each user during the query period that satisfies the Washout Period criteria (14 days). Under this condition, a user may have more than one incident episode.

**Minimum incidence type for the event will only consider events under the condition that the user has no prior history of the event previously (no time restriction). There may only be one event per user.

Glossary of Terms in Modular Program 5*

Eligible Members (incidence-based cohort) - Number of members eligible for incident diagnosis (defined by the washout period) with medical coverage during the query period.

Eligible Members (prevalence-based cohort) - Number of members with at least one day of medical coverage during the query period.

Enrollment Gap - Number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

Member-Days (incidence-based cohort) - Sum of all days of enrollment with medical coverage in the query period preceded by a washout period.

Member-Days (prevalence-based cohort) - Sum of all days members are enrolled with medical coverage during the query period.

New Patients (Members Vaccinated)- Number of members with incident diagnosis during the query period. Member must have no evidence of diagnosis of interest (defined by incidence criteria) in the prior washout period. A patient may only be counted once in a query period.

New Starts- Number of incident diagnoses during the query period. Patient must have no prior diagnoses in the washout period. For a minimum incidence type, an individual may have no more than one new start. For a multiple incidence type, an individual may have more than one new start.

Query Period - Period in which the modular program looks for diagnoses of interest.

Washout Period - Number of days a patient is required to have no evidence of prior diagnosis and continuous medical coverage.

*all terms may not be used in this report

Glossary of Terms in Modular Program 3*

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA).

Days at Risk - number of days supplied plus any episode gaps and exposure extension periods.

Eligible Members - Number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a “continuously enrolled” sequence.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode.

Incidence Type (drug/exposure)- *Minimum incidence type* will consider the first treatment episode in the query period as long as it is the first treatment episode in the user's entire available history. *Single* and *Multiple incidence types* will use the washout period to establish incidence, however *Single* will only consider the first treatment episode whereas *Multiple* will consider all qualifying incident treatment episodes.

Incidence Type (event/outcome)- *Minimum incidence type* considers the first event in a valid episode as long as it is the first event in the user's entire available history. *Multiple incidence type* uses the washout period to establish incidence and considers all qualifying incident treatment episodes. The program will only consider one event per episode, but the *Multiple incidence type* will consider more than one event per user if a user has more than one incident episode.

Lookback Period (pre-existing condition) - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

Member-Days - sum of all days of enrollment with medical and drug coverage** in the query period preceded by an exposure washout period.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered.

New Episodes (Vaccinations) - new treatment episodes; length of episode is determined by days supplied in one dispensing (or consecutive dispensings bridged by the episode gap).

New Users (Members Vaccinated) - number of members with incident exposure during the query period. Member must have no evidence of exposure (s) of interest (defined by incidence criteria) in the prior washout period. A user may only be counted once in a query period.

Principal Diagnosis - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. YES will only consider diagnoses flagged as Principal.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Total Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Washout Period (drug/exposure)** - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome)** - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

*all terms may not be used in this report

**incident treatment episodes must be incident to both the exposure and the event

Table 1a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine in Members Aged 0-72 Months

Vaccination	Prevalent					Incident							
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated	
PCV7	1,938,496	4,514,136	8,647,811	4,642,521,266	224.2	2.3	1,895,250	4,391,078	4,395,786	8,554,169	4,457,335,932	221.6	2.3
PCV13	1,110,544	1,834,009	8,647,811	4,642,521,266	128.4	1.7	1,098,614	1,810,306	1,812,116	8,554,279	4,494,080,282	128.4	1.6
Generic PCV	1,443,772	3,171,204	8,647,811	4,642,521,266	167.0	2.2	1,417,535	3,094,957	3,103,417	8,554,118	4,429,270,074	165.7	2.2

Table 1b. Summary of Prevalent and Incident Kawasaki's Disease Diagnoses in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator in Members Aged 0-72 Months

Diagnosis	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/1K Eligible Members	Events/Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/1K Eligible Members	Total Events/New Patient
Kawasaki's Disease (All Diagnoses)	4,380	15,109	8,647,811	4,642,521,266	0.51	3.45	4,174	4,174	14,301	8,554,120	4,517,049,973	0.49	3.43
Kawasaki's Disease (Principal Diagnoses Only)	2,088	2,253	8,647,811	4,642,521,266	0.24	1.08	2,042	2,042	2,206	8,554,273	4,518,161,851	0.00	1.08

Table 1c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, and Principal Diagnosis Indicator in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
	1,894,984	4,389,986	8,465,923	4,389,019,747	65,332,849	30	223.84	4.59
<i>No Principal Diagnosis Requirement</i>								
	1,894,869	4,389,720	8,465,777	4,387,964,855	65,328,810	43	223.83	6.58
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
	1,894,984	4,389,986	8,465,923	4,389,019,747	125,270,124	52	223.84	4.15
<i>No Principal Diagnosis Requirement</i>								
	1,894,869	4,389,720	8,465,777	4,387,964,855	125,262,157	79	223.83	6.31
PCV13								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
	1,098,175	1,809,652	8,466,035	4,425,763,273	26,813,263	8	129.72	2.98
<i>No Principal Diagnosis Requirement</i>								
	1,097,999	1,809,440	8,465,889	4,424,707,594	26,810,053	17	129.70	6.34
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
	1,098,175	1,809,652	8,466,035	4,425,763,273	51,110,849	13	129.72	2.54
<i>No Principal Diagnosis Requirement</i>								
	1,097,999	1,809,440	8,465,889	4,424,707,594	51,104,604	24	129.70	4.70

Table 1c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, and Principal Diagnosis Indicator in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
	1,313,817	1,753,704	8,463,204	4,297,618,657	243,832,897	128	155.24	5.25
<i>No Principal Diagnosis Requirement</i>								
	1,313,743	1,753,598	8,463,060	4,296,606,544	243,805,908	210	155.23	8.61
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
	1,313,817	1,753,704	8,463,204	4,297,618,657	267,139,415	131	155.24	4.90
<i>No Principal Diagnosis Requirement</i>								
	1,313,743	1,753,598	8,463,060	4,296,606,544	267,109,868	216	155.23	8.09

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent					Incident							
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated	
PCV7													
00M-01M	772	782	1,676,967	47,335,856	0.5	1.0	367	370	375	1,530,726	23,794,982	0.2	1.0
01M-02M	176,519	176,624	1,677,998	48,701,827	105.2	1.0	171,670	171,695	171,773	1,628,260	45,761,279	105.4	1.0
02M-03M	819,838	820,877	1,640,468	49,481,688	499.8	1.0	795,369	795,646	796,372	1,588,803	36,767,967	500.6	1.0
03M-04M	175,497	175,723	1,663,687	50,153,896	105.5	1.0	170,686	170,818	170,901	1,614,991	47,211,971	105.7	1.0
04M-05M	844,698	845,733	1,680,943	50,839,512	502.5	1.0	821,388	821,712	822,386	1,631,996	38,223,489	503.3	1.0
05M-06M	159,551	159,821	1,699,321	51,429,208	93.9	1.0	155,000	155,183	155,264	1,654,194	48,218,787	93.7	1.0
06M-07M	809,205	810,118	1,716,687	52,044,334	471.4	1.0	789,109	789,406	790,005	1,669,316	40,342,291	472.7	1.0
07M-08M	111,141	111,257	1,734,393	52,622,470	64.1	1.0	107,490	107,531	107,600	1,690,004	49,177,844	63.6	1.0
08M-09M	45,891	45,958	1,749,828	53,138,464	26.2	1.0	44,549	44,586	44,614	1,706,929	51,137,764	26.1	1.0
09M-10M	75,511	75,594	1,767,783	53,740,666	42.7	1.0	73,727	73,753	73,807	1,725,327	51,362,670	42.7	1.0
10M-11M	23,462	23,489	1,781,071	54,190,415	13.2	1.0	22,750	22,765	22,776	1,738,996	52,515,094	13.1	1.0
11M-12M	17,748	17,774	1,800,704	54,775,645	9.9	1.0	17,284	17,297	17,308	1,758,233	53,239,859	9.8	1.0
12M-13M	524,888	525,299	1,827,839	55,478,246	287.2	1.0	513,321	513,450	513,725	1,780,423	47,590,835	288.3	1.0
13M-14M	67,836	67,882	1,845,877	56,151,560	36.8	1.0	65,702	65,714	65,746	1,801,243	53,478,401	36.5	1.0
14M-15M	44,412	44,455	1,865,897	56,691,970	23.8	1.0	43,197	43,213	43,237	1,821,817	54,810,003	23.7	1.0
15M-16M	241,854	241,983	1,882,446	57,179,772	128.5	1.0	236,442	236,482	236,567	1,838,040	52,692,149	128.6	1.0
16M-17M	57,603	57,649	1,897,656	57,669,195	30.4	1.0	55,957	55,971	56,000	1,854,057	55,291,527	30.2	1.0
17M-18M	31,370	31,397	1,911,959	58,068,778	16.4	1.0	30,536	30,542	30,563	1,869,251	56,269,185	16.3	1.0
18M-19M	76,277	76,325	1,924,349	58,464,008	39.6	1.0	74,577	74,597	74,624	1,881,658	56,109,756	39.6	1.0
19M-20M	27,417	27,436	1,936,706	58,839,484	14.2	1.0	26,681	26,687	26,699	1,894,288	57,049,450	14.1	1.0
20M-21M	16,191	16,202	1,947,425	59,154,015	8.3	1.0	15,764	15,768	15,775	1,905,244	57,588,296	8.3	1.0
21M-22M	11,423	11,432	1,959,829	59,554,689	5.8	1.0	11,107	11,108	11,116	1,917,615	58,037,748	5.8	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent					Incident							
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated	
<i>PCV7 (Continued)</i>													
22M-23M	7,776	7,783	1,968,128	59,829,721	4.0	1.0	7,555	7,557	7,562	1,926,327	58,432,050	3.9	1.0
23M-24M	7,262	7,268	1,981,230	60,229,336	3.7	1.0	7,085	7,086	7,091	1,940,258	58,810,797	3.7	1.0
24M-25M	28,914	28,930	1,994,588	60,556,469	14.5	1.0	28,328	28,333	28,344	1,952,605	58,850,060	14.5	1.0
25M-26M	10,428	10,432	2,005,122	60,889,933	5.2	1.0	10,170	10,171	10,174	1,962,959	59,410,114	5.2	1.0
26M-27M	6,546	6,552	2,017,147	61,159,888	3.2	1.0	6,399	6,401	6,405	1,975,008	59,724,321	3.2	1.0
27M-28M	4,747	4,750	2,027,196	61,406,685	2.3	1.0	4,622	4,623	4,625	1,984,223	59,980,994	2.3	1.0
28M-29M	4,035	4,039	2,038,211	61,719,952	2.0	1.0	3,913	3,914	3,916	1,995,343	60,301,987	2.0	1.0
29M-30M	3,489	3,491	2,048,288	61,963,465	1.7	1.0	3,403	3,404	3,405	2,006,124	60,550,938	1.7	1.0
30M-31M	3,714	3,716	2,056,176	62,203,552	1.8	1.0	3,614	3,614	3,615	2,013,593	60,827,177	1.8	1.0
31M-32M	3,016	3,019	2,066,627	62,465,183	1.5	1.0	2,935	2,936	2,938	2,024,051	61,066,240	1.5	1.0
32M-33M	2,743	2,746	2,074,664	62,689,551	1.3	1.0	2,668	2,668	2,671	2,032,567	61,322,227	1.3	1.0
33M-34M	2,387	2,388	2,084,412	62,978,290	1.1	1.0	2,329	2,330	2,330	2,041,965	61,594,842	1.1	1.0
34M-35M	2,183	2,186	2,090,186	63,163,217	1.0	1.0	2,126	2,128	2,129	2,048,151	61,849,278	1.0	1.0
35M-36M	2,392	2,394	2,101,006	63,467,117	1.1	1.0	2,332	2,333	2,334	2,059,467	62,116,162	1.1	1.0
36M-37M	7,117	7,121	2,111,234	63,682,870	3.4	1.0	6,983	6,984	6,987	2,068,888	62,267,747	3.4	1.0
37M-38M	3,751	3,751	2,120,375	63,926,396	1.8	1.0	3,676	3,676	3,676	2,077,627	62,559,525	1.8	1.0
38M-39M	2,683	2,683	2,131,617	64,149,805	1.3	1.0	2,615	2,615	2,615	2,088,318	62,756,400	1.3	1.0
39M-40M	2,296	2,297	2,140,120	64,316,325	1.1	1.0	2,226	2,227	2,227	2,097,079	62,933,070	1.1	1.0
40M-41M	2,003	2,005	2,149,024	64,530,954	0.9	1.0	1,967	1,967	1,969	2,105,707	63,142,988	0.9	1.0
41M-42M	1,882	1,884	2,157,146	64,655,922	0.9	1.0	1,829	1,830	1,831	2,113,455	63,260,356	0.9	1.0
42M-43M	1,744	1,744	2,163,936	64,848,203	0.8	1.0	1,695	1,695	1,695	2,120,250	63,478,802	0.8	1.0
43M-44M	1,761	1,763	2,172,957	65,042,960	0.8	1.0	1,719	1,719	1,721	2,129,247	63,656,693	0.8	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations/ Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated
<i>PCV7 (Continued)</i>													
44M-45M	1,711	1,712	2,179,242	65,196,647	0.8	1.0	1,667	1,668	1,668	2,135,881	63,834,890	0.8	1.0
45M-46M	1,570	1,574	2,187,818	65,428,169	0.7	1.0	1,537	1,538	1,541	2,144,626	64,055,478	0.7	1.0
46M-47M	1,383	1,384	2,194,186	65,555,149	0.6	1.0	1,350	1,350	1,351	2,150,721	64,229,851	0.6	1.0
47M-48M	1,304	1,304	2,203,204	65,796,040	0.6	1.0	1,274	1,274	1,274	2,160,615	64,437,227	0.6	1.0
48M-49M	5,726	5,730	2,211,417	65,918,205	2.6	1.0	5,632	5,632	5,636	2,168,239	64,518,129	2.6	1.0
49M-50M	3,048	3,049	2,218,115	66,069,873	1.4	1.0	2,991	2,991	2,992	2,174,421	64,707,060	1.4	1.0
50M-51M	2,209	2,213	2,227,120	66,217,179	1.0	1.0	2,144	2,145	2,147	2,182,532	64,823,956	1.0	1.0
51M-52M	1,982	1,982	2,234,397	66,326,929	0.9	1.0	1,939	1,939	1,939	2,189,612	64,928,278	0.9	1.0
52M-53M	1,657	1,659	2,241,486	66,483,800	0.7	1.0	1,630	1,630	1,632	2,197,246	65,086,723	0.7	1.0
53M-54M	1,596	1,596	2,246,785	66,530,082	0.7	1.0	1,546	1,546	1,546	2,202,457	65,138,892	0.7	1.0
54M-55M	1,522	1,524	2,251,684	66,663,048	0.7	1.0	1,485	1,486	1,487	2,207,709	65,295,899	0.7	1.0
55M-56M	1,547	1,550	2,258,527	66,778,874	0.7	1.0	1,519	1,520	1,522	2,214,456	65,394,088	0.7	1.0
56M-57M	1,522	1,522	2,262,917	66,856,967	0.7	1.0	1,485	1,485	1,485	2,218,749	65,499,494	0.7	1.0
57M-58M	1,474	1,475	2,270,630	67,046,831	0.6	1.0	1,446	1,447	1,447	2,226,424	65,665,206	0.6	1.0
58M-59M	1,462	1,462	2,273,900	67,106,532	0.6	1.0	1,438	1,438	1,438	2,230,079	65,787,606	0.6	1.0
59M-60M	1,501	1,503	2,280,960	67,274,811	0.7	1.0	1,479	1,480	1,481	2,238,015	65,923,277	0.7	1.0
60M-61M	1,269	1,271	2,287,615	67,332,759	0.6	1.0	1,247	1,248	1,249	2,243,980	65,993,462	0.6	1.0
61M-62M	808	808	2,290,830	67,414,529	0.4	1.0	786	786	786	2,246,876	66,093,074	0.3	1.0
62M-63M	602	602	2,297,462	67,491,672	0.3	1.0	585	585	585	2,253,009	66,138,744	0.3	1.0
63M-64M	554	554	2,303,864	67,571,336	0.2	1.0	548	548	548	2,258,363	66,196,645	0.2	1.0
64M-65M	449	449	2,310,084	67,731,751	0.2	1.0	433	433	433	2,265,077	66,338,180	0.2	1.0
65M-66M	442	442	2,316,131	67,797,531	0.2	1.0	434	434	434	2,271,191	66,406,077	0.2	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations/ Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated
PCV7 (Continued)													
66M-67M	370	370	2,318,681	67,885,330	0.2	1.0	365	365	365	2,273,985	66,541,070	0.2	1.0
67M-68M	334	334	2,323,120	67,971,760	0.1	1.0	328	328	328	2,278,021	66,604,424	0.1	1.0
68M-69M	331	332	2,326,733	68,043,573	0.1	1.0	318	319	319	2,281,524	66,692,953	0.1	1.0
69M-70M	253	255	2,330,904	68,182,376	0.1	1.0	251	252	253	2,286,235	66,823,055	0.1	1.0
70M-71M	265	266	2,330,159	68,203,220	0.1	1.0	262	263	263	2,285,956	66,907,109	0.1	1.0
71M-72M	460	462	2,434,376	137,012,672	0.2	1.0	441	443	443	2,389,854	134,350,491	0.2	1.0
PCV13													
00M-01M	195	200	1,676,967	47,335,856	0.1	1.0	98	99	103	1,530,738	23,796,630	0.1	1.1
01M-02M	56,500	56,530	1,677,998	48,701,827	33.7	1.0	55,706	55,713	55,736	1,629,282	46,246,318	34.2	1.0
02M-03M	271,494	271,900	1,640,468	49,481,688	165.5	1.0	267,668	267,783	268,065	1,591,182	44,335,796	168.2	1.0
03M-04M	53,678	53,774	1,663,687	50,153,896	32.3	1.0	52,891	52,958	52,987	1,616,130	48,209,139	32.7	1.0
04M-05M	275,333	275,739	1,680,943	50,839,512	163.8	1.0	271,954	272,073	272,354	1,634,827	45,840,574	166.4	1.0
05M-06M	46,094	46,176	1,699,321	51,429,208	27.1	1.0	45,390	45,452	45,471	1,655,162	49,493,695	27.4	1.0
06M-07M	265,929	266,277	1,716,687	52,044,334	154.9	1.0	262,941	263,048	263,286	1,672,359	47,384,273	157.2	1.0
07M-08M	32,978	33,005	1,734,393	52,622,470	19.0	1.0	32,391	32,401	32,416	1,690,815	50,637,762	19.2	1.0
08M-09M	12,005	12,014	1,749,828	53,138,464	6.9	1.0	11,803	11,806	11,812	1,707,269	51,616,099	6.9	1.0
09M-10M	19,612	19,639	1,767,783	53,740,666	11.1	1.0	19,390	19,404	19,416	1,725,698	52,123,288	11.2	1.0
10M-11M	6,344	6,347	1,781,071	54,190,415	3.6	1.0	6,219	6,220	6,222	1,739,211	52,797,711	3.6	1.0
11M-12M	4,380	4,389	1,800,704	54,775,645	2.4	1.0	4,301	4,305	4,310	1,758,354	53,375,050	2.4	1.0
12M-13M	189,118	189,277	1,827,839	55,478,246	103.5	1.0	187,080	187,124	187,237	1,781,881	51,782,490	105.0	1.0
13M-14M	22,423	22,432	1,845,877	56,151,560	12.1	1.0	22,004	22,005	22,013	1,801,784	54,345,217	12.2	1.0
14M-15M	13,780	13,785	1,865,897	56,691,970	7.4	1.0	13,548	13,550	13,553	1,822,111	55,148,590	7.4	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations/ Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated
<i>PCV13 (Continued)</i>													
15M-16M	83,226	83,284	1,882,446	57,179,772	44.2	1.0	82,393	82,407	82,450	1,838,950	54,771,852	44.8	1.0
16M-17M	17,909	17,927	1,897,656	57,669,195	9.4	1.0	17,641	17,649	17,659	1,854,455	55,982,203	9.5	1.0
17M-18M	10,124	10,135	1,911,959	58,068,778	5.3	1.0	9,983	9,990	9,994	1,869,436	56,566,039	5.3	1.0
18M-19M	36,268	36,286	1,924,349	58,464,008	18.8	1.0	35,901	35,909	35,919	1,881,970	56,672,210	19.1	1.0
19M-20M	11,658	11,669	1,936,706	58,839,484	6.0	1.0	11,496	11,499	11,507	1,894,451	57,304,812	6.1	1.0
20M-21M	6,526	6,536	1,947,425	59,154,015	3.4	1.0	6,436	6,440	6,445	1,905,357	57,736,365	3.4	1.0
21M-22M	4,726	4,730	1,959,829	59,554,689	2.4	1.0	4,667	4,669	4,671	1,917,682	58,140,020	2.4	1.0
22M-23M	3,246		1,968,128	59,829,721	1.6		3,180	3,182	3,183	1,926,395	58,500,190	1.7	1.0
23M-24M	5,185	5,188	1,981,230	60,229,336	2.6	1.0	5,131	5,133	5,134	1,940,295	58,856,323	2.6	1.0
24M-25M	54,387	54,413	1,994,588	60,556,469	27.3	1.0	53,910	53,919	53,935	1,952,632	58,558,453	27.6	1.0
25M-26M	12,489	12,495	2,005,122	60,889,933	6.2	1.0	12,336	12,337	12,342	1,962,943	59,367,551	6.3	1.0
26M-27M	6,270	6,275	2,017,147	61,159,888	3.1	1.0	6,187	6,190	6,192	1,975,033	59,726,967	3.1	1.0
27M-28M	4,497	4,498	2,027,196	61,406,685	2.2	1.0	4,422	4,422	4,423	1,984,240	59,988,386	2.2	1.0
28M-29M	3,619	3,620	2,038,211	61,719,952	1.8	1.0	3,576	3,576	3,577	1,995,347	60,308,945	1.8	1.0
29M-30M	4,033	4,034	2,048,288	61,963,465	2.0	1.0	3,974	3,974	3,975	2,006,121	60,551,519	2.0	1.0
30M-31M	7,801	7,804	2,056,176	62,203,552	3.8	1.0	7,723	7,726	7,726	2,013,591	60,776,511	3.8	1.0
31M-32M	4,233	4,236	2,066,627	62,465,183	2.0	1.0	4,177	4,179	4,180	2,024,052	61,048,343	2.1	1.0
32M-33M	3,259	3,261	2,074,664	62,689,551	1.6	1.0	3,212	3,212	3,214	2,032,564	61,315,245	1.6	1.0
33M-34M	2,937	2,937	2,084,412	62,978,290	1.4	1.0	2,897	2,897	2,897	2,041,972	61,588,448	1.4	1.0
34M-35M	2,801	2,803	2,090,186	63,163,217	1.3	1.0	2,767	2,769	2,769	2,048,155	61,841,700	1.4	1.0
35M-36M	6,100	6,102	2,101,006	63,467,117	2.9	1.0	6,027	6,027	6,029	2,059,460	62,091,475	2.9	1.0
36M-37M	64,007	64,024	2,111,234	63,682,870	30.3	1.0	63,470	63,473	63,486	2,068,775	61,575,564	30.7	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations/ Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated
<i>PCV13 (Continued)</i>													
37M-38M	20,803	20,806	2,120,375	63,926,396	9.8	1.0	20,566	20,566	20,569	2,077,482	62,268,070	9.9	1.0
38M-39M	10,540	10,545	2,131,617	64,149,805	4.9	1.0	10,442	10,444	10,447	2,088,252	62,630,367	5.0	1.0
39M-40M	7,034	7,038	2,140,120	64,316,325	3.3	1.0	6,958	6,960	6,962	2,097,034	62,862,158	3.3	1.0
40M-41M	5,230	5,234	2,149,024	64,530,954	2.4	1.0	5,163	5,163	5,167	2,105,689	63,096,324	2.5	1.0
41M-42M	4,589	4,592	2,157,146	64,655,922	2.1	1.0	4,521	4,522	4,524	2,113,441	63,222,426	2.1	1.0
42M-43M	4,189	4,191	2,163,936	64,848,203	1.9	1.0	4,138	4,138	4,140	2,120,235	63,444,011	2.0	1.0
43M-44M	3,827	3,829	2,172,957	65,042,960	1.8	1.0	3,785	3,785	3,787	2,129,233	63,627,671	1.8	1.0
44M-45M	3,347	3,349	2,179,242	65,196,647	1.5	1.0	3,312	3,313	3,314	2,135,871	63,810,693	1.6	1.0
45M-46M	3,143	3,144	2,187,818	65,428,169	1.4	1.0	3,098	3,098	3,099	2,144,614	64,034,265	1.4	1.0
46M-47M	2,898	2,899	2,194,186	65,555,149	1.3	1.0	2,866	2,866	2,867	2,150,720	64,208,884	1.3	1.0
47M-48M	3,813	3,813	2,203,204	65,796,040	1.7	1.0	3,777	3,777	3,777	2,160,599	64,412,073	1.7	1.0
48M-49M	52,435	52,461	2,211,417	65,918,205	23.7	1.0	51,952	51,961	51,977	2,168,137	63,962,482	24.0	1.0
49M-50M	20,671	20,680	2,218,115	66,069,873	9.3	1.0	20,491	20,492	20,500	2,174,294	64,409,269	9.4	1.0
50M-51M	11,320	11,323	2,227,120	66,217,179	5.1	1.0	11,192	11,193	11,195	2,182,470	64,678,189	5.1	1.0
51M-52M	7,477	7,481	2,234,397	66,326,929	3.3	1.0	7,415	7,415	7,419	2,189,585	64,843,624	3.4	1.0
52M-53M	5,937	5,938	2,241,486	66,483,800	2.6	1.0	5,865	5,865	5,866	2,197,209	65,025,230	2.7	1.0
53M-54M	4,820	4,822	2,246,785	66,530,082	2.1	1.0	4,758	4,758	4,760	2,202,429	65,091,167	2.2	1.0
54M-55M	4,423	4,423	2,251,684	66,663,048	2.0	1.0	4,386	4,386	4,386	2,207,695	65,255,111	2.0	1.0
55M-56M	4,061	4,062	2,258,527	66,778,874	1.8	1.0	4,019	4,019	4,020	2,214,439	65,359,399	1.8	1.0
56M-57M	3,859	3,861	2,262,917	66,856,967	1.7	1.0	3,816	3,817	3,818	2,218,739	65,466,699	1.7	1.0
57M-58M	3,860	3,866	2,270,630	67,046,831	1.7	1.0	3,818	3,819	3,824	2,226,410	65,631,956	1.7	1.0
58M-59M	3,654	3,657	2,273,900	67,106,532	1.6	1.0	3,608	3,608	3,611	2,230,066	65,758,011	1.6	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations/ Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated
PCV13 (Continued)													
59M-60M	4,068	4,071	2,280,960	67,274,811	1.8	1.0	4,021	4,021	4,024	2,238,002	65,890,131	1.8	1.0
60M-61M	3,787	3,789	2,287,615	67,332,759	1.7	1.0	3,747	3,747	3,749	2,243,953	65,954,441	1.7	1.0
61M-62M	1,715	1,716	2,290,830	67,414,529	0.7	1.0	1,689	1,690	1,690	2,246,869	66,077,231	0.8	1.0
62M-63M	1,068	1,068	2,297,462	67,491,672	0.5	1.0	1,061	1,061	1,061	2,253,009	66,131,474	0.5	1.0
63M-64M	839	840	2,303,864	67,571,336	0.4	1.0	825	825	826	2,258,359	66,192,113	0.4	1.0
64M-65M	675	676	2,310,084	67,731,751	0.3	1.0	666	666	667	2,265,078	66,335,181	0.3	1.0
65M-66M	538	538	2,316,131	67,797,531	0.2	1.0	531	531	531	2,271,189	66,404,508	0.2	1.0
66M-67M	446	446	2,318,681	67,885,330	0.2	1.0	440	440	440	2,273,981	66,539,697	0.2	1.0
67M-68M	425	425	2,323,120	67,971,760	0.2	1.0	421	421	421	2,278,024	66,603,074	0.2	1.0
68M-69M	349	349	2,326,733	68,043,573	0.1	1.0	346	346	346	2,281,524	66,692,478	0.2	1.0
69M-70M	325	325	2,330,904	68,182,376	0.1	1.0	322	322	322	2,286,239	66,822,203	0.1	1.0
70M-71M	281	281	2,330,159	68,203,220	0.1	1.0	276	276	276	2,285,954	66,906,881	0.1	1.0
71M-72M	481	481	2,434,376	137,012,672	0.2	1.0	475	475	475	2,389,854	134,350,036	0.2	1.0
Generic PCV													
00M-01M	1,230	1,509	1,676,967	47,335,856	0.7	1.2	529	539	581	1,530,635	23,789,144	0.3	1.1
01M-02M	110,599	110,931	1,677,998	48,701,827	65.9	1.0	107,982	108,092	108,293	1,627,967	45,498,339	66.3	1.0
02M-03M	529,563	530,973	1,640,468	49,481,688	322.8	1.0	516,042	516,410	517,377	1,587,126	32,822,571	325.1	1.0
03M-04M	108,615	108,937	1,663,687	50,153,896	65.3	1.0	106,010	106,133	106,316	1,614,549	46,753,342	65.7	1.0
04M-05M	548,480	549,897	1,680,943	50,839,512	326.3	1.0	535,860	536,202	537,195	1,630,459	34,358,673	328.7	1.0
05M-06M	99,682	100,012	1,699,321	51,429,208	58.7	1.0	97,174	97,311	97,486	1,653,619	47,663,035	58.8	1.0
06M-07M	528,113	529,450	1,716,687	52,044,334	307.6	1.0	517,077	517,384	518,350	1,668,090	36,759,169	310.0	1.0
07M-08M	76,054	76,316	1,734,393	52,622,470	43.9	1.0	73,902	73,951	74,145	1,689,315	48,506,729	43.7	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent					Incident							
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated	
<i>Generic PCV (Continued)</i>													
08M-09M	27,663	27,788	1,749,828	53,138,464	15.8	1.0	26,918	26,953	27,031	1,706,762	50,944,920	15.8	1.0
09M-10M	45,056	45,211	1,767,783	53,740,666	25.5	1.0	44,125	44,168	44,272	1,725,181	51,080,208	25.6	1.0
10M-11M	14,861	14,914	1,781,071	54,190,415	8.3	1.0	14,455	14,466	14,505	1,738,902	52,402,121	8.3	1.0
11M-12M	11,645	11,697	1,800,704	54,775,645	6.5	1.0	11,363	11,373	11,408	1,758,168	53,184,649	6.5	1.0
12M-13M	360,564	361,433	1,827,839	55,478,246	197.3	1.0	353,813	353,966	354,628	1,780,009	45,126,067	198.8	1.0
13M-14M	48,339	48,480	1,845,877	56,151,560	26.2	1.0	46,989	47,014	47,117	1,800,851	53,006,167	26.1	1.0
14M-15M	29,402	29,474	1,865,897	56,691,970	15.8	1.0	28,670	28,685	28,738	1,821,679	54,643,353	15.7	1.0
15M-16M	163,253	163,575	1,882,446	57,179,772	86.7	1.0	160,170	160,235	160,480	1,837,660	51,557,311	87.2	1.0
16M-17M	39,045	39,138	1,897,656	57,669,195	20.6	1.0	38,037	38,050	38,122	1,853,772	54,947,952	20.5	1.0
17M-18M	20,722	20,800	1,911,959	58,068,778	10.8	1.0	20,237	20,254	20,310	1,869,129	56,127,276	10.8	1.0
18M-19M	55,850	55,968	1,924,349	58,464,008	29.0	1.0	54,873	54,902	54,982	1,881,492	55,618,497	29.2	1.0
19M-20M	20,059	20,103	1,936,706	58,839,484	10.4	1.0	19,610	19,618	19,652	1,894,166	56,842,257	10.4	1.0
20M-21M	11,655	11,700	1,947,425	59,154,015	6.0	1.0	11,396	11,404	11,439	1,905,174	57,483,760	6.0	1.0
21M-22M	8,284	8,316	1,959,829	59,554,689	4.2	1.0	8,070	8,074	8,102	1,917,562	57,963,110	4.2	1.0
22M-23M	5,701	5,720	1,968,128	59,829,721	2.9	1.0	5,558	5,560	5,576	1,926,291	58,380,553	2.9	1.0
23M-24M	6,382	6,397	1,981,230	60,229,336	3.2	1.0	6,268	6,270	6,281	1,940,222	58,760,122	3.2	1.0
24M-25M	43,492	43,572	1,994,588	60,556,469	21.8	1.0	42,947	42,963	43,024	1,952,465	58,141,798	22.0	1.0
25M-26M	12,567	12,599	2,005,122	60,889,933	6.3	1.0	12,333	12,339	12,365	1,962,828	59,185,146	6.3	1.0
26M-27M	7,257	7,274	2,017,147	61,159,888	3.6	1.0	7,122	7,126	7,138	1,974,955	59,619,877	3.6	1.0
27M-28M	5,271	5,281	2,027,196	61,406,685	2.6	1.0	5,166	5,166	5,174	1,984,175	59,911,328	2.6	1.0
28M-29M	4,506	4,523	2,038,211	61,719,952	2.2	1.0	4,423	4,426	4,438	1,995,303	60,244,997	2.2	1.0
29M-30M	4,266	4,275	2,048,288	61,963,465	2.1	1.0	4,181	4,181	4,189	2,006,093	60,497,427	2.1	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent					Incident							
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated	
<i>Generic PCV (Continued)</i>													
30M-31M	6,208	6,226	2,056,176	62,203,552	3.0	1.0	6,121	6,124	6,139	2,013,553	60,717,589	3.0	1.0
31M-32M	4,233	4,247	2,066,627	62,465,183	2.0	1.0	4,160	4,164	4,173	2,024,016	60,999,910	2.1	1.0
32M-33M	3,549	3,561	2,074,664	62,689,551	1.7	1.0	3,473	3,474	3,485	2,032,528	61,271,399	1.7	1.0
33M-34M	3,135	3,147	2,084,412	62,978,290	1.5	1.0	3,071	3,075	3,083	2,041,939	61,549,641	1.5	1.0
34M-35M	2,983	2,998	2,090,186	63,163,217	1.4	1.0	2,936	2,938	2,950	2,048,123	61,806,644	1.4	1.0
35M-36M	4,672	4,683	2,101,006	63,467,117	2.2	1.0	4,587	4,588	4,598	2,059,424	62,056,029	2.2	1.0
36M-37M	38,774	38,820	2,111,234	63,682,870	18.4	1.0	38,410	38,415	38,455	2,068,715	61,442,945	18.6	1.0
37M-38M	13,989	14,010	2,120,375	63,926,396	6.6	1.0	13,814	13,814	13,834	2,077,446	62,189,746	6.6	1.0
38M-39M	7,713	7,729	2,131,617	64,149,805	3.6	1.0	7,609	7,610	7,624	2,088,217	62,578,255	3.6	1.0
39M-40M	5,491	5,507	2,140,120	64,316,325	2.6	1.0	5,407	5,409	5,423	2,097,007	62,820,757	2.6	1.0
40M-41M	4,340	4,352	2,149,024	64,530,954	2.0	1.0	4,263	4,263	4,275	2,105,663	63,060,653	2.0	1.0
41M-42M	3,931	3,944	2,157,146	64,655,922	1.8	1.0	3,867	3,871	3,880	2,113,413	63,190,319	1.8	1.0
42M-43M	3,556	3,571	2,163,936	64,848,203	1.6	1.0	3,499	3,502	3,514	2,120,218	63,414,084	1.7	1.0
43M-44M	3,513	3,524	2,172,957	65,042,960	1.6	1.0	3,468	3,470	3,478	2,129,214	63,597,591	1.6	1.0
44M-45M	3,107	3,113	2,179,242	65,196,647	1.4	1.0	3,060	3,061	3,065	2,135,854	63,782,540	1.4	1.0
45M-46M	3,001	3,005	2,187,818	65,428,169	1.4	1.0	2,953	2,953	2,957	2,144,603	64,006,679	1.4	1.0
46M-47M	2,718	2,727	2,194,186	65,555,149	1.2	1.0	2,682	2,683	2,691	2,150,706	64,184,497	1.2	1.0
47M-48M	3,145	3,154	2,203,204	65,796,040	1.4	1.0	3,102	3,103	3,111	2,160,581	64,389,160	1.4	1.0
48M-49M	29,545	29,600	2,211,417	65,918,205	13.4	1.0	29,224	29,236	29,278	2,168,103	63,861,207	13.5	1.0
49M-50M	12,776	12,805	2,218,115	66,069,873	5.8	1.0	12,648	12,652	12,676	2,174,269	64,342,036	5.8	1.0
50M-51M	7,514	7,533	2,227,120	66,217,179	3.4	1.0	7,416	7,418	7,434	2,182,433	64,632,999	3.4	1.0
51M-52M	5,268	5,281	2,234,397	66,326,929	2.4	1.0	5,206	5,207	5,218	2,189,569	64,807,484	2.4	1.0

Table 2a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations/ Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated
<i>Generic PCV (Continued)</i>													
52M-53M	4,413	4,425	2,241,486	66,483,800	2.0	1.0	4,353	4,353	4,365	2,197,183	64,993,983	2.0	1.0
53M-54M	3,769	3,778	2,246,785	66,530,082	1.7	1.0	3,711	3,712	3,719	2,202,401	65,062,895	1.7	1.0
54M-55M	3,541	3,555	2,251,684	66,663,048	1.6	1.0	3,499	3,502	3,513	2,207,676	65,227,515	1.6	1.0
55M-56M	3,385	3,394	2,258,527	66,778,874	1.5	1.0	3,348	3,350	3,357	2,214,425	65,331,362	1.5	1.0
56M-57M	3,323	3,335	2,262,917	66,856,967	1.5	1.0	3,279	3,281	3,291	2,218,724	65,440,203	1.5	1.0
57M-58M	3,315	3,326	2,270,630	67,046,831	1.5	1.0	3,276	3,277	3,287	2,226,387	65,606,080	1.5	1.0
58M-59M	3,227	3,240	2,273,900	67,106,532	1.4	1.0	3,187	3,189	3,200	2,230,054	65,732,422	1.4	1.0
59M-60M	3,442	3,456	2,280,960	67,274,811	1.5	1.0	3,404	3,409	3,418	2,237,985	65,863,746	1.5	1.0
60M-61M	3,477	3,490	2,287,615	67,332,759	1.5	1.0	3,431	3,434	3,443	2,243,943	65,922,861	1.5	1.0
61M-62M	1,753	1,757	2,290,830	67,414,529	0.8	1.0	1,714	1,716	1,718	2,246,861	66,058,429	0.8	1.0
62M-63M	1,236	1,247	2,297,462	67,491,672	0.5	1.0	1,220	1,220	1,231	2,253,000	66,116,896	0.5	1.0
63M-64M	1,054	1,055	2,303,864	67,571,336	0.5	1.0	1,042	1,042	1,043	2,258,354	66,180,218	0.5	1.0
64M-65M	854	861	2,310,084	67,731,751	0.4	1.0	829	829	836	2,265,069	66,324,746	0.4	1.0
65M-66M	797	801	2,316,131	67,797,531	0.3	1.0	784	785	788	2,271,185	66,394,829	0.3	1.0
66M-67M	658	659	2,318,681	67,885,330	0.3	1.0	650	650	650	2,273,977	66,531,061	0.3	1.0
67M-68M	616	617	2,323,120	67,971,760	0.3	1.0	608	608	609	2,278,016	66,595,460	0.3	1.0
68M-69M	564	566	2,326,733	68,043,573	0.2	1.0	552	553	554	2,281,518	66,685,051	0.2	1.0
69M-70M	470	472	2,330,904	68,182,376	0.2	1.0	466	467	468	2,286,233	66,815,913	0.2	1.0
70M-71M	483	487	2,330,159	68,203,220	0.2	1.0	475	477	479	2,285,951	66,900,589	0.2	1.0
71M-72M	872	883	2,434,376	137,012,672	0.4	1.0	855	858	865	2,389,849	134,338,092	0.4	1.0

Table 2b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (All Diagnoses)</i>													
00M-01M	18	25	1,676,967	47,335,856	0.0	1.4	9	9	10	1,530,734	23,796,990	0.0	1.1
01M-02M	25	37	1,677,998	48,701,827	0.0	1.5	21	21	31	1,629,502	46,476,475	0.0	1.5
02M-03M	32	66	1,640,468	49,481,688	0.0	2.1	25	25	51	1,592,658	47,953,329	0.0	2.0
03M-04M	53	120	1,663,687	50,153,896	0.0	2.3	30	30	56	1,616,463	48,621,431	0.0	1.9
04M-05M	78	159	1,680,943	50,839,512	0.0	2.0	39	39	73	1,636,082	49,361,126	0.0	1.9
05M-06M	97	206	1,699,321	51,429,208	0.1	2.1	42	42	76	1,655,545	49,985,229	0.0	1.8
06M-07M	99	214	1,716,687	52,044,334	0.1	2.2	46	46	97	1,673,252	50,643,814	0.0	2.1
07M-08M	119	217	1,734,393	52,622,470	0.1	1.8	50	50	91	1,691,251	51,224,718	0.0	1.8
08M-09M	118	205	1,749,828	53,138,464	0.1	1.7	57	57	101	1,707,195	51,778,570	0.0	1.8
09M-10M	134	222	1,767,783	53,740,666	0.1	1.7	59	59	103	1,725,568	52,361,845	0.0	1.7
10M-11M	137	220	1,781,071	54,190,415	0.1	1.6	61	61	104	1,738,998	52,884,625	0.0	1.7
11M-12M	161	270	1,800,704	54,775,645	0.1	1.7	77	77	119	1,758,059	53,409,364	0.0	1.5
12M-13M	158	277	1,827,839	55,478,246	0.1	1.8	59	59	104	1,781,811	53,999,365	0.0	1.8
13M-14M	144	252	1,845,877	56,151,560	0.1	1.8	65	65	124	1,801,688	54,745,448	0.0	1.9
14M-15M	140	226	1,865,897	56,691,970	0.1	1.6	62	62	112	1,821,732	55,276,597	0.0	1.8
15M-16M	158	252	1,882,446	57,179,772	0.1	1.6	64	64	114	1,838,736	55,764,618	0.0	1.8
16M-17M	159	239	1,897,656	57,669,195	0.1	1.5	70	70	113	1,854,138	56,264,207	0.0	1.6
17M-18M	172	298	1,911,959	58,068,778	0.1	1.7	87	87	167	1,868,929	56,669,469	0.0	1.9
18M-19M	185	294	1,924,349	58,464,008	0.1	1.6	73	73	141	1,881,444	57,093,862	0.0	1.9
19M-20M	187	302	1,936,706	58,839,484	0.1	1.6	72	72	130	1,893,831	57,466,303	0.0	1.8
20M-21M	142	255	1,947,425	59,154,015	0.1	1.8	62	62	128	1,904,649	57,804,273	0.0	2.1
21M-22M	148	222	1,959,829	59,554,689	0.1	1.5	60	60	104	1,916,935	58,180,653	0.0	1.7

Table 2b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (All Diagnoses) (Continued)</i>													
22M-23M	159	249	1,968,128	59,829,721	0.1	1.6	66	66	116	1,925,593	58,519,347	0.0	1.8
23M-24M	161	244	1,981,230	60,229,336	0.1	1.5	68	68	113	1,939,463	58,873,955	0.0	1.7
24M-25M	177	265	1,994,588	60,556,469	0.1	1.5	70	70	122	1,951,852	59,193,692	0.0	1.7
25M-26M	168	250	2,005,122	60,889,933	0.1	1.5	61	61	114	1,962,121	59,545,466	0.0	1.9
26M-27M	161	253	2,017,147	61,159,888	0.1	1.6	73	73	134	1,974,129	59,790,938	0.0	1.8
27M-28M	151	263	2,027,196	61,406,685	0.1	1.7	67	67	138	1,983,310	60,019,379	0.0	2.1
28M-29M	160	275	2,038,211	61,719,952	0.1	1.7	69	69	152	1,994,373	60,326,926	0.0	2.2
29M-30M	165	253	2,048,288	61,963,465	0.1	1.5	68	68	122	2,005,113	60,566,293	0.0	1.8
30M-31M	154	210	2,056,176	62,203,552	0.1	1.4	56	56	86	2,012,556	60,844,898	0.0	1.5
31M-32M	178	296	2,066,627	62,465,183	0.1	1.7	83	83	165	2,022,977	61,073,711	0.0	2.0
32M-33M	162	241	2,074,664	62,689,551	0.1	1.5	59	59	112	2,031,454	61,325,051	0.0	1.9
33M-34M	152	226	2,084,412	62,978,290	0.1	1.5	56	56	88	2,040,837	61,592,746	0.0	1.6
34M-35M	145	229	2,090,186	63,163,217	0.1	1.6	66	66	113	2,046,996	61,842,638	0.0	1.7
35M-36M	140	219	2,101,006	63,467,117	0.1	1.6	56	56	104	2,058,287	62,108,659	0.0	1.9
36M-37M	158	247	2,111,234	63,682,870	0.1	1.6	59	59	102	2,067,724	62,321,029	0.0	1.7
37M-38M	162	234	2,120,375	63,926,396	0.1	1.4	61	61	102	2,076,422	62,577,800	0.0	1.7
38M-39M	135	208	2,131,617	64,149,805	0.1	1.5	65	65	109	2,087,105	62,756,861	0.0	1.7
39M-40M	143	213	2,140,120	64,316,325	0.1	1.5	56	56	90	2,095,848	62,926,660	0.0	1.6
40M-41M	156	220	2,149,024	64,530,954	0.1	1.4	81	81	124	2,104,469	63,132,383	0.0	1.5
41M-42M	136	203	2,157,146	64,655,922	0.1	1.5	45	45	81	2,112,198	63,246,833	0.0	1.8
42M-43M	146	218	2,163,936	64,848,203	0.1	1.5	66	66	121	2,119,008	63,463,755	0.0	1.8
43M-44M	157	259	2,172,957	65,042,960	0.1	1.6	75	75	138	2,127,980	63,641,449	0.0	1.8

Table 2b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (All Diagnoses) (Continued)</i>													
44M-45M	133	227	2,179,242	65,196,647	0.1	1.7	54	54	98	2,134,593	63,818,056	0.0	1.8
45M-46M	129	218	2,187,818	65,428,169	0.1	1.7	52	52	81	2,143,340	64,037,644	0.0	1.6
46M-47M	118	218	2,194,186	65,555,149	0.1	1.8	62	62	117	2,149,435	64,209,333	0.0	1.9
47M-48M	141	259	2,203,204	65,796,040	0.1	1.8	60	60	103	2,159,326	64,414,668	0.0	1.7
48M-49M	146	245	2,211,417	65,918,205	0.1	1.7	57	57	89	2,166,961	64,548,514	0.0	1.6
49M-50M	127	210	2,218,115	66,069,873	0.1	1.7	62	62	89	2,173,141	64,713,364	0.0	1.4
50M-51M	133	208	2,227,120	66,217,179	0.1	1.6	63	63	100	2,181,253	64,816,282	0.0	1.6
51M-52M	142	187	2,234,397	66,326,929	0.1	1.3	57	57	86	2,188,312	64,915,679	0.0	1.5
52M-53M	124	190	2,241,486	66,483,800	0.1	1.5	55	55	93	2,195,967	65,070,288	0.0	1.7
53M-54M	113	181	2,246,785	66,530,082	0.1	1.6	59	59	111	2,201,178	65,120,893	0.0	1.9
54M-55M	135	236	2,251,684	66,663,048	0.1	1.7	64	64	126	2,206,408	65,276,440	0.0	2.0
55M-56M	137	187	2,258,527	66,778,874	0.1	1.4	52	52	81	2,213,132	65,374,771	0.0	1.6
56M-57M	120	184	2,262,917	66,856,967	0.1	1.5	52	52	93	2,217,420	65,479,274	0.0	1.8
57M-58M	117	169	2,270,630	67,046,831	0.1	1.4	52	52	80	2,225,103	65,644,531	0.0	1.5
58M-59M	126	191	2,273,900	67,106,532	0.1	1.5	61	61	104	2,228,763	65,767,331	0.0	1.7
59M-60M	130	197	2,280,960	67,274,811	0.1	1.5	65	65	108	2,236,705	65,902,872	0.0	1.7
60M-61M	135	178	2,287,615	67,332,759	0.1	1.3	59	59	76	2,242,662	65,972,528	0.0	1.3
61M-62M	126	177	2,290,830	67,414,529	0.1	1.4	64	64	97	2,245,542	66,063,882	0.0	1.5
62M-63M	113	157	2,297,462	67,491,672	0.0	1.4	50	50	72	2,251,678	66,107,220	0.0	1.4
63M-64M	97	149	2,303,864	67,571,336	0.0	1.5	47	47	75	2,257,048	66,163,836	0.0	1.6
64M-65M	107	147	2,310,084	67,731,751	0.0	1.4	45	45	72	2,263,762	66,304,762	0.0	1.6
65M-66M	107	147	2,316,131	67,797,531	0.0	1.4	54	54	79	2,269,887	66,372,619	0.0	1.5

Table 2b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (All Diagnoses) (Continued)</i>													
66M-67M	114	169	2,318,681	67,885,330	0.0	1.5	58	58	93	2,272,686	66,506,892	0.0	1.6
67M-68M	115	161	2,323,120	67,971,760	0.0	1.4	43	43	65	2,276,715	66,569,410	0.0	1.5
68M-69M	101	133	2,326,733	68,043,573	0.0	1.3	44	44	59	2,280,221	66,658,294	0.0	1.3
69M-70M	102	141	2,330,904	68,182,376	0.0	1.4	49	49	72	2,284,946	66,787,619	0.0	1.5
70M-71M	93	123	2,330,159	68,203,220	0.0	1.3	42	42	59	2,284,673	66,872,026	0.0	1.4
71M-72M	157	267	2,434,376	137,012,672	0.1	1.7	76	76	141	2,388,572	134,279,423	0.0	1.9
<i>Kawasaki's Disease (Principal Diagnoses Only)</i>													
00M-01M	5	5	1,676,967	47,335,856	0.0	1.0	2	2	2	1,530,739	23,797,101	0.0	1.0
01M-02M	8	8	1,677,998	48,701,827	0.0	1.0	6	6	6	1,629,512	46,476,947	0.0	1.0
02M-03M	17	20	1,640,468	49,481,688	0.0	1.2	17	17	20	1,592,681	47,954,088	0.0	1.2
03M-04M	22	25	1,663,687	50,153,896	0.0	1.1	19	19	20	1,616,493	48,622,459	0.0	1.1
04M-05M	33	36	1,680,943	50,839,512	0.0	1.1	32	32	33	1,636,120	49,362,391	0.0	1.0
05M-06M	38	41	1,699,321	51,429,208	0.0	1.1	32	32	34	1,655,593	49,986,836	0.0	1.1
06M-07M	32	33	1,716,687	52,044,334	0.0	1.0	32	32	33	1,673,310	50,645,745	0.0	1.0
07M-08M	30	32	1,734,393	52,622,470	0.0	1.1	27	27	29	1,691,319	51,227,103	0.0	1.1
08M-09M	34	36	1,749,828	53,138,464	0.0	1.1	32	32	34	1,707,280	51,781,582	0.0	1.1
09M-10M	37	38	1,767,783	53,740,666	0.0	1.0	35	35	36	1,725,674	52,365,300	0.0	1.0
10M-11M	42	43	1,781,071	54,190,415	0.0	1.0	41	41	42	1,739,119	52,888,739	0.0	1.0
11M-12M	46	46	1,800,704	54,775,645	0.0	1.0	43	43	43	1,758,198	53,414,188	0.0	1.0
12M-13M	28	30	1,827,839	55,478,246	0.0	1.1	27	27	29	1,781,979	54,005,035	0.0	1.1
13M-14M	35	40	1,845,877	56,151,560	0.0	1.1	33	33	38	1,801,879	54,751,775	0.0	1.2
14M-15M	33	35	1,865,897	56,691,970	0.0	1.1	32	32	34	1,821,950	55,283,776	0.0	1.1

Table 2b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (Principal Diagnoses Only) (Continued)</i>													
15M-16M	40	41	1,882,446	57,179,772	0.0	1.0	38	38	39	1,838,976	55,772,437	0.0	1.0
16M-17M	39	41	1,897,656	57,669,195	0.0	1.1	37	37	39	1,854,394	56,272,548	0.0	1.1
17M-18M	57	59	1,911,959	58,068,778	0.0	1.0	54	54	56	1,869,205	56,678,376	0.0	1.0
18M-19M	45	46	1,924,349	58,464,008	0.0	1.0	42	42	43	1,881,737	57,103,427	0.0	1.0
19M-20M	44	47	1,936,706	58,839,484	0.0	1.1	43	43	46	1,894,148	57,476,446	0.0	1.1
20M-21M	33	35	1,947,425	59,154,015	0.0	1.1	32	32	34	1,904,986	57,814,952	0.0	1.1
21M-22M	35	35	1,959,829	59,554,689	0.0	1.0	35	35	35	1,917,283	58,191,879	0.0	1.0
22M-23M	38	41	1,968,128	59,829,721	0.0	1.1	37	37	40	1,925,958	58,530,916	0.0	1.1
23M-24M	40	40	1,981,230	60,229,336	0.0	1.0	38	38	38	1,939,841	58,886,175	0.0	1.0
24M-25M	39	41	1,994,588	60,556,469	0.0	1.1	35	35	37	1,952,248	59,206,393	0.0	1.1
25M-26M	35	37	2,005,122	60,889,933	0.0	1.1	33	33	35	1,962,538	59,558,570	0.0	1.1
26M-27M	48	50	2,017,147	61,159,888	0.0	1.0	46	46	48	1,974,548	59,804,164	0.0	1.0
27M-28M	41	41	2,027,196	61,406,685	0.0	1.0	37	37	37	1,983,733	60,033,038	0.0	1.0
28M-29M	46	50	2,038,211	61,719,952	0.0	1.1	46	46	50	1,994,820	60,340,847	0.0	1.1
29M-30M	37	39	2,048,288	61,963,465	0.0	1.1	37	37	39	2,005,567	60,580,478	0.0	1.1
30M-31M	32	32	2,056,176	62,203,552	0.0	1.0	30	30	30	2,013,022	60,859,619	0.0	1.0
31M-32M	51	53	2,066,627	62,465,183	0.0	1.0	50	50	52	2,023,463	61,088,931	0.0	1.0
32M-33M	31	34	2,074,664	62,689,551	0.0	1.1	30	30	33	2,031,958	61,340,750	0.0	1.1
33M-34M	37	37	2,084,412	62,978,290	0.0	1.0	31	31	31	2,041,345	61,608,675	0.0	1.0
34M-35M	31	32	2,090,186	63,163,217	0.0	1.0	29	29	29	2,047,520	61,859,050	0.0	1.0
35M-36M	40	41	2,101,006	63,467,117	0.0	1.0	40	40	41	2,058,832	62,125,380	0.0	1.0
36M-37M	33	36	2,111,234	63,682,870	0.0	1.1	29	29	32	2,068,260	62,337,906	0.0	1.1

Table 2b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (Principal Diagnoses Only) (Continued)</i>													
37M-38M	33	33	2,120,375	63,926,396	0.0	1.0	31	31	31	2,076,978	62,595,098	0.0	1.0
38M-39M	28	31	2,131,617	64,149,805	0.0	1.1	26	26	28	2,087,665	62,774,638	0.0	1.1
39M-40M	29	29	2,140,120	64,316,325	0.0	1.0	26	26	26	2,096,422	62,944,645	0.0	1.0
40M-41M	30	30	2,149,024	64,530,954	0.0	1.0	29	29	29	2,105,052	63,150,826	0.0	1.0
41M-42M	24	24	2,157,146	64,655,922	0.0	1.0	23	23	23	2,112,807	63,265,492	0.0	1.0
42M-43M	32	33	2,163,936	64,848,203	0.0	1.0	30	30	31	2,119,611	63,482,499	0.0	1.0
43M-44M	41	43	2,172,957	65,042,960	0.0	1.0	41	41	43	2,128,594	63,660,530	0.0	1.0
44M-45M	27	27	2,179,242	65,196,647	0.0	1.0	24	24	24	2,135,225	63,837,612	0.0	1.0
45M-46M	22	25	2,187,818	65,428,169	0.0	1.1	20	20	23	2,143,971	64,057,237	0.0	1.2
46M-47M	27	28	2,194,186	65,555,149	0.0	1.0	27	27	28	2,150,063	64,228,969	0.0	1.0
47M-48M	31	31	2,203,204	65,796,040	0.0	1.0	30	30	30	2,159,965	64,434,512	0.0	1.0
48M-49M	20	22	2,211,417	65,918,205	0.0	1.1	20	20	22	2,167,596	64,568,224	0.0	1.1
49M-50M	22	22	2,218,115	66,069,873	0.0	1.0	21	21	21	2,173,789	64,733,667	0.0	1.0
50M-51M	26	26	2,227,120	66,217,179	0.0	1.0	26	26	26	2,181,920	64,836,848	0.0	1.0
51M-52M	23	24	2,234,397	66,326,929	0.0	1.0	20	20	21	2,188,981	64,936,311	0.0	1.1
52M-53M	19	20	2,241,486	66,483,800	0.0	1.1	18	18	19	2,196,631	65,091,002	0.0	1.1
53M-54M	24	30	2,246,785	66,530,082	0.0	1.3	24	24	30	2,201,854	65,141,778	0.0	1.3
54M-55M	33	35	2,251,684	66,663,048	0.0	1.1	32	32	34	2,207,099	65,297,669	0.0	1.1
55M-56M	18	18	2,258,527	66,778,874	0.0	1.0	17	17	17	2,213,830	65,396,345	0.0	1.0
56M-57M	25	26	2,262,917	66,856,967	0.0	1.0	24	24	25	2,218,136	65,501,278	0.0	1.0
57M-58M	29	29	2,270,630	67,046,831	0.0	1.0	26	26	26	2,225,817	65,666,445	0.0	1.0
58M-59M	22	23	2,273,900	67,106,532	0.0	1.0	21	21	22	2,229,475	65,789,324	0.0	1.0

Table 2b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Age Group in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (Principal Diagnoses Only) (Continued)</i>													
59M-60M	25	26	2,280,960	67,274,811	0.0	1.0	25	25	26	2,237,422	65,925,064	0.0	1.0
60M-61M	25	27	2,287,615	67,332,759	0.0	1.1	25	25	27	2,243,391	65,995,164	0.0	1.1
61M-62M	20	20	2,290,830	67,414,529	0.0	1.0	18	18	18	2,246,289	66,086,869	0.0	1.0
62M-63M	17	17	2,297,462	67,491,672	0.0	1.0	16	16	16	2,252,434	66,130,296	0.0	1.0
63M-64M	17	19	2,303,864	67,571,336	0.0	1.1	17	17	19	2,257,806	66,187,130	0.0	1.1
64M-65M	13	14	2,310,084	67,731,751	0.0	1.1	13	13	14	2,264,527	66,327,990	0.0	1.1
65M-66M	24	24	2,316,131	67,797,531	0.0	1.0	23	23	23	2,270,652	66,395,904	0.0	1.0
66M-67M	24	25	2,318,681	67,885,330	0.0	1.0	23	23	24	2,273,452	66,530,336	0.0	1.0
67M-68M	17	17	2,323,120	67,971,760	0.0	1.0	16	16	16	2,277,495	66,592,991	0.0	1.0
68M-69M	11	12	2,326,733	68,043,573	0.0	1.1	11	11	12	2,281,001	66,681,877	0.0	1.1
69M-70M	23	24	2,330,904	68,182,376	0.0	1.0	21	21	22	2,285,723	66,811,076	0.0	1.0
70M-71M	15	15	2,330,159	68,203,220	0.0	1.0	15	15	15	2,285,441	66,895,372	0.0	1.0
71M-72M	25	28	2,434,376	137,012,672	0.0	1.1	24	24	27	2,389,343	134,325,993	0.0	1.1

Table 2c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Age in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
00M to 03M	1,036,882	1,138,412	1,956,879	155,218,441	16,921,079	3	529.87	1.77
04M to 05M	939,381	976,740	1,739,518	86,666,735	14,534,207	5	540.02	3.44
06M to 11M	1,002,015	1,055,098	2,160,884	300,767,349	15,711,079	7	463.71	4.46
12M to 23M	1,048,579	1,087,870	2,839,648	674,543,411	16,204,855	15	369.26	9.26
24M to 59M	119,117	126,092	5,253,101	2,291,484,978	1,875,737	0	22.68	0.00
60M to 71M	5,419	5,774	3,307,717	799,441,394	85,892	0	1.64	0.00
<i>No Principal Diagnosis Requirement</i>								
00M to 03M	1,036,863	1,138,393	1,956,871	155,216,276	16,920,792	3	529.86	1.77
04M to 05M	939,353	976,711	1,739,478	86,664,256	14,533,772	5	540.02	3.44
06M to 11M	1,001,972	1,055,051	2,160,813	300,749,048	15,710,352	10	463.70	6.37
12M to 23M	1,048,447	1,087,729	2,839,454	674,438,505	16,202,721	23	369.24	14.20
24M to 59M	119,090	126,065	5,252,615	2,290,840,875	1,875,313	2	22.67	10.66
60M to 71M	5,416	5,771	3,306,967	799,167,499	85,860	0	1.64	0.00

Table 2c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Age in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7 (Continued)								
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
00M to 03M	1,036,882	1,138,412	1,956,879	155,218,441	32,407,766	6	529.87	1.85
04M to 05M	939,381	976,740	1,739,518	86,666,735	27,863,903	11	540.02	3.95
06M to 11M	1,002,015	1,055,098	2,160,884	300,767,349	30,134,228	15	463.71	4.98
12M to 23M	1,048,579	1,087,870	2,839,648	674,543,411	31,103,174	20	369.26	6.43
24M to 59M	119,117	126,092	5,253,101	2,291,484,978	3,596,275	0	22.68	0.00
60M to 71M	5,419	5,774	3,307,717	799,441,394	164,778	0	1.64	0.00
<i>No Principal Diagnosis Requirement</i>								
00M to 03M	1,036,863	1,138,393	1,956,871	155,216,276	32,407,209	7	529.86	2.16
04M to 05M	939,353	976,711	1,739,478	86,664,256	27,863,062	12	540.02	4.31
06M to 11M	1,001,972	1,055,051	2,160,813	300,749,048	30,132,765	23	463.70	7.63
12M to 23M	1,048,447	1,087,729	2,839,454	674,438,505	31,098,955	34	369.24	10.93
24M to 59M	119,090	126,065	5,252,615	2,290,840,875	3,595,448	3	22.67	8.34
60M to 71M	5,416	5,771	3,306,967	799,167,499	164,718	0	1.64	0.00

Table 2c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Age in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV13								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
00M to 03M	345,615	376,516	1,957,773	164,278,631	5,564,994	0	176.53	0.00
04M to 05M	306,318	317,480	1,740,818	95,558,750	4,697,201	2	175.96	4.26
06M to 11M	323,902	337,125	2,161,472	310,919,346	4,991,901	1	149.85	2.00
12M to 23M	388,717	399,444	2,839,774	684,114,801	5,921,027	3	136.88	5.07
24M to 59M	364,938	368,497	5,253,083	2,288,125,647	5,480,744	2	69.47	3.65
60M to 71M	10,545	10,590	3,307,696	799,365,009	157,396	0	3.19	0.00
<i>No Principal Diagnosis Requirement</i>								
00M to 03M	345,613	376,514	1,957,765	164,276,254	5,564,964	0	176.53	0.00
04M to 05M	306,312	317,473	1,740,778	95,555,968	4,697,093	2	175.96	4.26
06M to 11M	323,887	337,105	2,161,401	310,900,623	4,991,613	1	149.85	2.00
12M to 23M	388,665	399,391	2,839,580	684,008,681	5,920,212	8	136.87	13.51
24M to 59M	364,814	368,373	5,252,597	2,287,482,867	5,478,865	6	69.45	10.95
60M to 71M	10,539	10,584	3,306,946	799,091,169	157,306	0	3.19	0.00

Table 2c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Age in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV13 (Continued)								
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
00M to 03M	345,615	376,516	1,957,773	164,278,631	10,576,495	0	176.53	0.00
04M to 05M	306,318	317,480	1,740,818	95,558,750	8,934,719	4	175.96	4.48
06M to 11M	323,902	337,125	2,161,472	310,919,346	9,502,679	1	149.85	1.05
12M to 23M	388,717	399,444	2,839,774	684,114,801	11,294,183	5	136.88	4.43
24M to 59M	364,938	368,497	5,253,083	2,288,125,647	10,501,397	3	69.47	2.86
60M to 71M	10,545	10,590	3,307,696	799,365,009	301,376	0	3.19	0.00
<i>No Principal Diagnosis Requirement</i>								
00M to 03M	345,613	376,514	1,957,765	164,276,254	10,576,437	0	176.53	0.00
04M to 05M	306,312	317,473	1,740,778	95,555,968	8,934,513	4	175.96	4.48
06M to 11M	323,887	337,105	2,161,401	310,900,623	9,502,135	2	149.85	2.10
12M to 23M	388,665	399,391	2,839,580	684,008,681	11,292,583	10	136.87	8.86
24M to 59M	364,814	368,373	5,252,597	2,287,482,867	10,497,734	8	69.45	7.62
60M to 71M	10,539	10,584	3,306,946	799,091,169	301,202	0	3.19	0.00

Table 2c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Age in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
00M to 03M	746,742	762,512	1,955,808	149,414,951	150,643,724	83	381.81	5.51
04M to 05M	224,943	229,222	1,713,550	79,852,601	30,068,083	16	131.27	5.32
06M to 11M	227,120	234,586	2,125,351	286,904,860	29,536,690	13	106.86	4.40
12M to 23M	335,969	343,614	2,807,778	651,844,207	28,773,611	15	119.66	5.21
24M to 59M	173,414	175,824	5,215,826	2,259,465,893	4,652,407	1	33.25	2.15
60M to 71M	7,906	7,946	3,294,993	795,430,141	158,382	0	2.40	0.00
<i>No Principal Diagnosis Requirement</i>								
00M to 03M	746,734	762,504	1,955,800	149,413,067	150,631,741	125	381.80	8.30
04M to 05M	224,936	229,215	1,713,561	79,847,039	30,065,868	24	131.27	7.98
06M to 11M	227,107	234,573	2,125,304	286,918,177	29,531,484	32	106.86	10.84
12M to 23M	335,936	343,579	2,807,545	651,730,050	28,767,946	23	119.65	8.00
24M to 59M	173,377	175,786	5,215,248	2,258,847,488	4,650,549	6	33.24	12.90
60M to 71M	7,901	7,941	3,294,218	795,152,214	158,320	0	2.40	0.00

Table 2c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Age in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV (Continued)								
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
00M to 03M	746,742	762,512	1,955,808	149,414,951	160,538,899	86	381.81	5.36
04M to 05M	224,943	229,222	1,713,550	79,852,601	33,135,540	16	131.27	4.83
06M to 11M	227,120	234,586	2,125,351	286,904,860	32,706,310	13	106.86	3.97
12M to 23M	335,969	343,614	2,807,778	651,844,207	33,446,988	15	119.66	4.48
24M to 59M	173,414	175,824	5,215,826	2,259,465,893	7,045,135	1	33.25	1.42
60M to 71M	7,906	7,946	3,294,993	795,430,141	266,543	0	2.40	0.00
<i>No Principal Diagnosis Requirement</i>								
00M to 03M	746,734	762,504	1,955,800	149,413,067	160,526,192	131	381.80	8.16
04M to 05M	224,936	229,215	1,713,561	79,847,039	33,133,143	24	131.27	7.24
06M to 11M	227,107	234,573	2,125,304	286,918,177	32,700,684	32	106.86	9.79
12M to 23M	335,936	343,579	2,807,545	651,730,050	33,440,735	23	119.65	6.88
24M to 59M	173,377	175,786	5,215,248	2,258,847,488	7,042,689	6	33.24	8.52
60M to 71M	7,901	7,941	3,294,218	795,152,214	266,425	0	2.40	0.00

Table 3a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Sex in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations/ Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations/ New Member Vaccinated
PCV7													
Female	941,460	2,192,862	4,204,199	2,255,177,676	223.9	2.3	920,514	2,132,902	2,135,102	4,159,020	2,165,199,116	221.3	2.3
Male	992,112	2,309,985	4,415,433	2,367,606,346	224.7	2.3	969,920	2,247,196	2,249,689	4,367,220	2,273,034,649	222.1	2.3
Unknown	4,924	11,289	28,179	19,737,244	174.7	2.3	4,816	10,980	10,995	27,929	19,102,167	172.4	2.3
PCV13													
Female	540,601	893,126	4,204,199	2,255,177,676	128.6	1.7	534,843	881,606	882,493	4,159,067	2,183,016,550	128.6	1.7
Male	568,347	938,637	4,415,433	2,367,606,346	128.7	1.7	562,191	926,479	927,401	4,367,283	2,291,837,942	128.7	1.6
Unknown	1,596	2,246	28,179	19,737,244	56.6	1.4	1,580	2,221	2,222	27,929	19,225,790	56.6	1.4
Generic PCV													
Female	701,091	1,541,974	4,204,199	2,255,177,676	166.8	2.2	688,336	1,504,947	1,508,967	4,158,996	2,151,530,195	165.5	2.2
Male	739,070	1,621,427	4,415,433	2,367,606,346	167.4	2.2	725,652	1,582,397	1,586,824	4,367,193	2,258,671,818	166.2	2.2
Unknown	3,611	7,803	28,179	19,737,244	128.1	2.2	3,547	7,613	7,626	27,929	19,068,061	127.0	2.1

Table 3b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Sex in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (All Diagnoses)</i>													
Female	1,742	5,590	4,204,199	2,255,177,676	0.4	3.2	1,662	1,662	5,280	4,159,005	2,194,416,888	0.4	3.2
Male	2,630	9,481	4,415,433	2,367,606,346	0.6	3.6	2,504	2,504	8,983	4,367,186	2,303,378,451	0.6	3.6
Unknown	8	38	28,179	19,737,244	0.3	4.8	8	8	38	27,929	19,254,634	0.3	4.8
<i>Kawasaki's Disease (Principal Diagnoses Only)</i>													
Female	828	876	4,204,199	2,255,177,676	0.2	1.1	810	810	857	4,159,067	2,194,858,219	0.2	1.1
Male	1,256	1,373	4,415,433	2,367,606,346	0.3	1.1	1,228	1,228	1,345	4,367,277	2,304,048,141	0.3	1.1
Unknown	4	4	28,179	19,737,244	0.1	1.0	4	4	4	27,929	19,255,491	0.1	1.0

Table 3c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Sex in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
Female	920,405	2,132,459	4,115,776	2,132,060,640	31,736,238	9	223.63	2.84
Male	969,777	2,246,570	4,322,467	2,238,194,275	33,433,642	21	224.36	6.28
Unknown	4,802	10,957	27,680	18,764,832	162,969	0	173.48	0.00
<i>No Principal Diagnosis Requirement</i>								
Female	920,359	2,132,338	4,115,716	2,131,642,365	31,734,401	15	223.62	4.73
Male	969,709	2,246,426	4,322,382	2,237,558,611	33,431,455	28	224.35	8.38
Unknown	4,801	10,956	27,679	18,763,879	162,954	0	173.45	0.00
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
Female	920,405	2,132,459	4,115,776	2,132,060,640	60,854,203	16	223.63	2.63
Male	969,777	2,246,570	4,322,467	2,238,194,275	64,103,446	36	224.36	5.62
Unknown	4,802	10,957	27,680	18,764,832	312,475	0	173.48	0.00
<i>No Principal Diagnosis Requirement</i>								
Female	920,359	2,132,338	4,115,716	2,131,642,365	60,850,596	27	223.62	4.44
Male	969,709	2,246,426	4,322,382	2,237,558,611	64,099,115	52	224.35	8.11
Unknown	4,801	10,956	27,679	18,763,879	312,446	0	173.45	0.00

Table 3c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Sex in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV13								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
Female	534,660	881,329	4,115,824	2,149,878,136	13,059,116	4	129.90	3.06
Male	561,938	926,105	4,322,531	2,256,996,975	13,721,061	4	130.00	2.92
Unknown	1,577	2,218	27,680	18,888,162	33,086	0	56.97	0.00
<i>No Principal Diagnosis Requirement</i>								
Female	534,586	881,242	4,115,764	2,149,459,357	13,057,804	6	129.89	4.59
Male	561,836	925,980	4,322,446	2,256,361,042	13,719,163	11	129.98	8.02
Unknown	1,577	2,218	27,679	18,887,195	33,086	0	56.97	0.00
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
Female	534,660	881,329	4,115,824	2,149,878,136	24,893,165	5	129.90	2.01
Male	561,938	926,105	4,322,531	2,256,996,975	26,154,166	8	130.00	3.06
Unknown	1,577	2,218	27,680	18,888,162	63,518	0	56.97	0.00
<i>No Principal Diagnosis Requirement</i>								
Female	534,586	881,242	4,115,764	2,149,459,357	24,890,620	8	129.89	3.21
Male	561,836	925,980	4,322,446	2,256,361,042	26,150,466	16	129.98	6.12
Unknown	1,577	2,218	27,679	18,887,195	63,518	0	56.97	0.00

Table 3c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Sex in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member-Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
Female	637,835	849,868	4,114,482	2,087,566,271	118,451,582	41	155.02	3.46
Male	672,643	899,601	4,321,042	2,191,427,922	124,771,185	87	155.67	6.97
Unknown	3,339	4,235	27,680	18,624,464	610,130	0	120.63	0.00
<i>No Principal Diagnosis Requirement</i>								
Female	637,805	849,823	4,114,423	2,087,262,017	118,438,253	76	155.02	6.42
Male	672,599	899,540	4,320,958	2,190,724,570	124,757,525	134	155.66	10.74
Unknown	3,339	4,235	27,679	18,619,957	610,130	0	120.63	0.00
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
Female	637,835	849,868	4,114,482	2,087,566,271	129,748,410	42	155.02	3.24
Male	672,643	899,601	4,321,042	2,191,427,922	136,724,294	89	155.67	6.51
Unknown	3,339	4,235	27,680	18,624,464	666,711	0	120.63	0.00
<i>No Principal Diagnosis Requirement</i>								
Female	637,805	849,823	4,114,423	2,087,262,017	129,733,994	79	155.02	6.09
Male	672,599	899,540	4,320,958	2,190,724,570	136,709,163	137	155.66	10.02
Unknown	3,339	4,235	27,679	18,619,957	666,711	0	120.63	0.00

Table 4a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Year in Members Aged 0-72 Months

Group	Prevalent					Incident							
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Vaccinations / Member Vaccinated	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations / New Member Vaccinated
PCV7													
2000	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2001	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2002	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2003	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2004	190,377	327,293	1,194,855	292,395,030	159.3	1.7	180,983	307,233	307,430	1,178,807	271,465,605	15.4	1.7
2005	234,951	392,985	1,237,378	301,591,071	189.9	1.7	231,340	385,551	385,818	1,227,182	289,607,816	18.9	1.7
2006	230,678	398,185	1,321,575	326,391,751	174.5	1.7	226,992	390,310	390,583	1,309,492	313,238,422	17.3	1.7
2007	260,953	446,807	1,492,935	354,229,976	174.8	1.7	255,802	436,253	436,541	1,478,904	338,977,422	17.3	1.7
2008	713,152	1,262,496	3,629,529	900,582,291	196.5	1.8	694,012	1,212,791	1,214,127	3,581,716	846,489,339	19.4	1.7
2009	655,871	1,161,406	3,483,700	884,079,490	188.3	1.8	648,232	1,143,904	1,145,249	3,462,418	851,300,390	18.7	1.8
2010	345,879	474,254	3,192,172	813,592,355	108.4	1.4	340,653	465,208	465,648	3,173,625	791,580,859	10.7	1.4
2011	35,421	48,934	2,892,713	725,720,122	12.2	1.4	34,886	48,095	48,134	2,879,501	711,921,847	1.2	1.4
2012	1,638	1,776	523,081	43,939,180	3.1	1.1	1,606	1,733	1,736	522,621	42,754,232	0.3	1.1
PCV13													
2000	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2001	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2002	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2003	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2004	0	0	1,194,855	292,395,030	0.0	0.0	0	0	0	1,178,853	275,824,219	0.0	0.0
2005	0	0	1,237,378	301,591,071	0.0	0.0	0	0	0	1,227,291	295,028,177	0.0	0.0
2006	0	0	1,321,575	326,391,751	0.0	0.0	0	0	0	1,309,627	318,726,227	0.0	0.0
2007	0	0	1,492,935	354,229,976	0.0	0.0	0	0	0	1,479,078	345,114,519	0.0	0.0

Table 4a. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine and Year in Members Aged 0-72 Months

Group	Prevalent					Incident							
	Members Vaccinated	Total Number of Vaccinations	Eligible Members	Member-Days	Members Vaccinated/ 1K Eligible Members	Members Newly Vaccinated	Number of New Vaccinations	Total Number of Vaccinations	Eligible Members	Member-Days	New Members Vaccinated/ 1K Eligible Members	Total Vaccinations / New Member Vaccinated	
PCV13 (Continued)													
2008	0	0	3,629,529	900,582,291	0	0	0	0	3,581,881	863,572,897	0	0	
2009	28	29	3,483,700	884,079,490	0	1.0	26	27	3,462,826	867,332,935	0	1.0	
2010	619,143	815,402	3,192,172	813,592,355	194.0	1.3	613,426	806,703	807,301	3,173,815	787,259,835	19.3	1.3
2011	630,655	973,977	2,892,713	725,720,122	218.0	1.5	623,391	960,029	961,116	2,879,312	699,069,251	21.7	1.5
2012	39,725	44,601	523,081	43,939,180	75.9	1.1	38,963	43,547	43,564	522,621	42,152,222	7.5	1.1
Generic PCV													
2000	0	0	0	0	0	0	0	0	0	0	0	0	0
2001	0	0	0	0	0	0	0	0	0	0	0	0	0
2002	0	0	0	0	0	0	0	0	0	0	0	0	0
2003	0	0	0	0	0	0	0	0	0	0	0	0	0
2004	79,989	129,385	1,194,855	292,395,030	66.9	1.6	76,210	121,879	122,031	1,178,807	271,362,788	64.7	2
2005	104,254	166,566	1,237,378	301,591,071	84.3	1.6	102,548	163,251	163,430	1,227,181	289,507,492	83.6	1.6
2006	107,532	176,432	1,321,575	326,391,751	81.4	1.6	105,710	172,809	172,998	1,309,490	313,144,595	80.7	1.6
2007	128,812	209,109	1,492,935	354,229,976	86.3	1.6	126,165	204,004	204,230	1,478,903	338,881,363	85.3	1.6
2008	358,253	601,379	3,629,529	900,582,291	98.7	1.7	348,222	576,739	578,303	3,581,709	846,224,061	97.2	1.7
2009	356,366	606,432	3,483,700	884,079,490	102.3	1.7	352,059	595,653	597,618	3,462,407	850,588,449	101.7	1.7
2010	446,734	693,848	3,192,172	813,592,355	139.9	1.6	442,057	682,825	684,725	3,173,561	779,838,044	139.3	1.5
2011	374,212	559,425	2,892,713	725,720,122	129.4	1.5	369,662	549,876	551,599	2,879,293	697,705,414	128.4	1.5
2012	25,667	28,628	523,081	43,939,180	49.1	1.1	25,199	27,921	27,992	522,621	42,017,868	48.2	1.1

Table 4b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Year in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (All Diagnoses)</i>													
2000	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2001	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2002	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2003	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2004	356	901	1,194,855	292,395,030	0.0	2.5	322	322	783	1,178,820	275,760,653	0.3	2.4
2005	341	1,013	1,237,378	301,591,071	0.0	3.0	253	253	733	1,227,000	294,901,829	0.2	2.9
2006	351	829	1,321,575	326,391,751	0.0	2.4	253	253	644	1,309,248	318,576,984	0.2	2.5
2007	378	964	1,492,935	354,229,976	0.0	2.6	278	278	791	1,478,642	344,947,219	0.2	2.8
2008	1,066	3,044	3,629,529	900,582,291	0.0	2.9	898	898	2,599	3,581,338	863,261,900	0.3	2.9
2009	1,134	3,258	3,483,700	884,079,490	0.0	2.9	839	839	2,590	3,461,776	866,886,967	0.2	3.1
2010	992	2,553	3,192,172	813,592,355	0.0	2.6	701	701	1,977	3,172,628	797,817,728	0.2	2.8
2011	832	2,405	2,892,713	725,720,122	0.0	2.9	591	591	1,988	2,878,239	712,149,139	0.2	3.4
2012	69	142	523,081	43,939,180	0.0	2.1	39	39	95	522,276	42,747,554	0.1	2.4
<i>Kawasaki's Disease (Principal Diagnoses Only)</i>													
2000	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2001	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2002	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2003	0	0	0	0	0.0	0.0	0	0	0	0	0	0.0	0.0
2004	141	156	1,194,855	292,395,030	0.1	1.1	134	134	149	1,178,846	275,801,206	0.1	1.1
2005	148	163	1,237,378	301,591,071	0.1	1.1	140	140	155	1,227,178	294,971,873	0.1	1.1
2006	137	150	1,321,575	326,391,751	0.1	1.1	134	134	146	1,309,446	318,650,687	0.1	1.1
2007	163	174	1,492,935	354,229,976	0.1	1.1	160	160	171	1,478,849	345,021,088	0.1	1.1

Table 4b. Summary of Prevalent and Incident Vaccination Use in the MSDD between January 1, 2004 and March 31, 2012, by Principal Diagnosis Indicator and Year in Members Aged 0-72 Months

Group	Prevalent						Incident						
	Patients	Total Number of Events	Eligible Members	Member-Days	Patients/ 1K Eligible Members	Events/ Patient	New Patients	New Events	Total Number of Events	Eligible Members	Member-Days	New Patients/ 1K Eligible Members	Total Events/ New Patient
<i>Kawasaki's Disease (Principal Diagnoses Only) (Continued)</i>													
2008	423	460	3,629,529	900,582,291	0.1	1.1	404	404	439	3,581,592	863,422,588	0.1	1.1
2009	423	449	3,483,700	884,079,490	0.1	1.1	413	413	436	3,462,334	867,114,447	0.1	1.1
2010	348	366	3,192,172	813,592,355	0.1	1.1	339	339	357	3,173,249	798,052,799	0.1	1.1
2011	301	312	2,892,713	725,720,122	0.1	1.0	296	296	307	2,878,860	712,365,587	0.1	1.0
2012	23	23	523,081	43,939,180	0.0	1.0	22	22	22	522,432	42,761,576	0.0	1.0

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	180,951	307,153	1,164,281	267,389,370	4,573,362	2	155.42	4.37
2005	231,311	385,469	1,211,728	285,245,913	5,737,314	3	190.89	5.23
2006	226,949	390,231	1,293,052	308,374,277	5,809,081	2	175.51	3.44
2007	255,757	436,140	1,460,154	333,794,134	6,489,474	2	175.16	3.08
2008	693,910	1,212,520	3,538,021	833,852,754	18,051,107	6	196.13	3.32
2009	648,122	1,143,587	3,418,839	838,187,299	17,006,747	10	189.57	5.88
2010	340,589	465,080	3,132,267	779,258,927	6,928,793	5	108.74	7.22
2011	34,877	48,075	2,841,607	700,786,053	711,867	0	12.27	0.00
2012	1,606	1,731	515,224	42,131,020	25,104	0	3.12	0.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7 (Continued)								
14 Day Episode Extension Period								
<i>No Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	180,934	307,126	1,164,257	267,351,446	4,572,957	2	155.41	4.37
2005	231,293	385,449	1,211,559	285,180,527	5,737,009	4	190.91	6.97
2006	226,938	390,218	1,292,865	308,304,917	5,808,881	3	175.53	5.16
2007	255,746	436,119	1,459,960	333,725,448	6,489,164	1	175.17	1.54
2008	693,862	1,212,450	3,537,780	833,698,618	18,050,008	15	196.13	8.31
2009	648,076	1,143,514	3,418,302	837,971,547	17,005,649	11	189.59	6.47
2010	340,559	465,043	3,131,674	779,035,597	6,928,246	7	108.75	10.10
2011	34,874	48,070	2,841,010	700,578,926	711,792	0	12.28	0.00
2012	1,606	1,731	515,075	42,117,829	25,104	0	3.12	0.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7 (Continued)								
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	180,951	307,153	1,164,281	267,389,370	8,772,638	4	155.42	4.56
2005	231,311	385,469	1,211,728	285,245,913	11,003,687	6	190.89	5.45
2006	226,949	390,231	1,293,052	308,374,277	11,139,988	2	175.51	1.80
2007	255,757	436,140	1,460,154	333,794,134	12,441,488	5	175.16	4.02
2008	693,910	1,212,520	3,538,021	833,852,754	34,621,653	12	196.13	3.47
2009	648,122	1,143,587	3,418,839	838,187,299	32,589,431	15	189.57	4.60
2010	340,589	465,080	3,132,267	779,258,927	13,299,416	8	108.74	6.02
2011	34,877	48,075	2,841,607	700,786,053	1,356,592	0	12.27	0.00
2012	1,606	1,731	515,224	42,131,020	45,231	0	3.12	0.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV7 (Continued)								
28 Day Episode Extension Period								
<i>No Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	180,934	307,126	1,164,257	267,351,446	8,771,861	4	155.41	4.56
2005	231,293	385,449	1,211,559	285,180,527	11,003,076	8	190.91	7.27
2006	226,938	390,218	1,292,865	308,304,917	11,139,592	3	175.53	2.69
2007	255,746	436,119	1,459,960	333,725,448	12,440,880	7	175.17	5.63
2008	693,862	1,212,450	3,537,780	833,698,618	34,619,418	27	196.13	7.80
2009	648,076	1,143,514	3,418,302	837,971,547	32,587,291	20	189.59	6.14
2010	340,559	465,043	3,131,674	779,035,597	13,298,361	10	108.75	7.52
2011	34,874	48,070	2,841,010	700,578,926	1,356,447	0	12.28	0.00
2012	1,606	1,731	515,075	42,117,829	45,231	0	3.12	0.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV13								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	0	0	1,164,326	271,747,345	0	0	0.00	0.00
2005	0	0	1,211,837	290,665,438	0	0	0.00	0.00
2006	0	0	1,293,187	313,861,426	0	0	0.00	0.00
2007	0	0	1,460,328	339,930,296	0	0	0.00	0.00
2008	0	0	3,538,188	850,934,419	0	0	0.00	0.00
2009	24	25	3,419,248	854,217,685	375	0	0.01	0.00
2010	613,200	806,418	3,132,459	774,940,390	11,988,313	4	195.76	3.34
2011	623,160	959,676	2,841,417	687,937,102	14,199,423	2	219.31	1.41
2012	38,951	43,533	515,224	41,529,172	625,152	2	75.60	31.99

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV13 (Continued)								
14 Day Episode Extension Period								
<i>No Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	0	0	1,164,302	271,709,058	0	0	0.00	0.00
2005	0	0	1,211,668	290,599,765	0	0	0.00	0.00
2006	0	0	1,293,000	313,791,853	0	0	0.00	0.00
2007	0	0	1,460,134	339,861,337	0	0	0.00	0.00
2008	0	0	3,537,947	850,779,243	0	0	0.00	0.00
2009	24	25	3,418,711	854,000,893	375	0	0.01	0.00
2010	613,098	806,310	3,131,866	774,718,072	11,986,681	7	195.76	5.84
2011	623,074	959,577	2,840,820	687,731,318	14,197,920	8	219.33	5.63
2012	38,946	43,528	515,075	41,516,055	625,077	2	75.61	32.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV13 (Continued)								
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	0	0	1,164,326	271,747,345	0	0	0.00	0.00
2005	0	0	1,211,837	290,665,438	0	0	0.00	0.00
2006	0	0	1,293,187	313,861,426	0	0	0.00	0.00
2007	0	0	1,460,328	339,930,296	0	0	0.00	0.00
2008	0	0	3,538,188	850,934,419	0	0	0.00	0.00
2009	24	25	3,419,248	854,217,685	711	0	0.01	0.00
2010	613,200	806,418	3,132,459	774,940,390	22,966,369	7	195.76	3.05
2011	623,160	959,676	2,841,417	687,937,102	27,025,859	4	219.31	1.48
2012	38,951	43,533	515,224	41,529,172	1,117,910	2	75.60	17.89

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
PCV13 (Continued)								
28 Day Episode Extension Period								
<i>No Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	0	0	1,164,302	271,709,058	0	0	0.00	0.00
2005	0	0	1,211,668	290,599,765	0	0	0.00	0.00
2006	0	0	1,293,000	313,791,853	0	0	0.00	0.00
2007	0	0	1,460,134	339,861,337	0	0	0.00	0.00
2008	0	0	3,537,947	850,779,243	0	0	0.00	0.00
2009	24	25	3,418,711	854,000,893	711	0	0.01	0.00
2010	613,098	806,310	3,131,866	774,718,072	22,963,191	11	195.76	4.79
2011	623,074	959,577	2,840,820	687,731,318	27,022,937	11	219.33	4.07
2012	38,946	43,528	515,075	41,516,055	1,117,765	2	75.61	17.89

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV								
14 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	75,232	88,959	1,164,057	266,613,008	12,383,502	4	64.63	3.23
2005	78,232	92,750	1,207,778	282,726,498	12,382,937	9	64.77	7.27
2006	81,926	98,686	1,286,584	305,308,138	15,490,818	9	63.68	5.81
2007	101,286	121,772	1,452,301	330,171,433	21,849,666	12	69.74	5.49
2008	323,810	389,933	3,528,209	827,624,994	74,887,309	52	91.78	6.94
2009	262,780	318,315	3,400,091	825,769,327	53,289,620	25	77.29	4.69
2010	308,711	358,471	3,101,961	752,265,962	38,037,656	15	99.52	3.94
2011	243,053	274,328	2,801,222	668,391,710	15,294,641	2	86.77	1.31
2012	10,240	10,490	486,891	38,747,587	216,748	0	21.03	0.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV (Continued)								
14 Day Episode Extension Period								
<i>No Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	75,228	88,954	1,164,034	266,560,660	12,381,635	9	64.63	7.27
2005	78,230	92,748	1,207,556	282,632,131	12,382,169	13	64.78	10.50
2006	81,923	98,683	1,286,309	305,203,508	15,489,620	11	63.69	7.10
2007	101,283	121,767	1,452,023	330,089,530	21,847,675	17	69.75	7.78
2008	323,792	389,913	3,528,006	827,486,575	74,875,929	82	91.78	10.95
2009	262,767	318,301	3,399,651	825,594,298	53,283,285	48	77.29	9.01
2010	308,680	358,438	3,101,437	752,080,433	38,035,112	23	99.53	6.05
2011	243,031	274,305	2,800,730	668,223,303	15,293,750	7	86.77	4.58
2012	10,239	10,489	486,757	38,736,106	216,733	0	21.04	0.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV (Continued)								
28 Day Episode Extension Period								
<i>Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	75,232	88,959	1,164,057	266,613,008	13,581,927	5	64.63	3.68
2005	78,232	92,750	1,207,778	282,726,498	13,626,783	9	64.77	6.60
2006	81,926	98,686	1,286,584	305,308,138	16,812,262	9	63.68	5.35
2007	101,286	121,772	1,452,301	330,171,433	23,476,975	12	69.74	5.11
2008	323,810	389,933	3,528,209	827,624,994	80,121,135	52	91.78	6.49
2009	262,780	318,315	3,400,091	825,769,327	57,529,081	26	77.29	4.52
2010	308,711	358,471	3,101,961	752,265,962	42,835,210	16	99.52	3.74
2011	243,053	274,328	2,801,222	668,391,710	18,829,010	2	86.77	1.06
2012	10,240	10,490	486,891	38,747,587	327,032	0	21.03	0.00

Table 4c: Summary of Incident Vaccine Use and Kawasaki's Disease events in the MSDD between January 1, 2004 and March 31, 2012, by Vaccine, Episode Extension Period, Principal Diagnosis Indicator, and Year in Members Aged 0-72 Months

	Members Newly Vaccinated	New Treatment Episodes	Eligible Members	Member Days	Days at Risk	Number of Events	New Members Vaccinated/ 1K Eligible Members	Number of Events/ 10M Days at Risk
Generic PCV (Continued)								
28 Day Episode Extension Period								
<i>No Principal Diagnosis Requirement</i>								
2000	0	0	0	0	0	0	0.00	0.00
2001	0	0	0	0	0	0	0.00	0.00
2002	0	0	0	0	0	0	0.00	0.00
2003	0	0	0	0	0	0	0.00	0.00
2004	75,228	88,954	1,164,034	266,560,660	13,579,920	10	64.63	7.36
2005	78,230	92,748	1,207,556	282,632,131	13,625,931	13	64.78	9.54
2006	81,923	98,683	1,286,309	305,203,508	16,810,991	12	63.69	7.14
2007	101,283	121,767	1,452,023	330,089,530	23,474,833	18	69.75	7.67
2008	323,792	389,913	3,528,006	827,486,575	80,109,042	83	91.78	10.36
2009	262,767	318,301	3,399,651	825,594,298	57,522,259	49	77.29	8.52
2010	308,680	358,438	3,101,437	752,080,433	42,832,120	24	99.53	5.60
2011	243,031	274,305	2,800,730	668,223,303	18,827,769	7	86.77	3.72
2012	10,239	10,489	486,757	38,736,106	327,003	0	21.04	0.00

Appendix A. List of Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), and International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) Codes Included in this Request

Code Type	Code
PCV7*	
CPT	90669
PCV13**	
CPT	90670
Generic PCV	
HCPCS	G0009
HCPCS	S0195
ICD-9-CM	V03.82
ICD-9-CM	V06.6
Kawasaki's Disease	
ICD-9-CM	446.1

*Four National Drug Codes (NDCs) were also used to identify PCV7.

**Two National Drug Codes (NDCs) were also used to identify PCV13.